Anti-VISTA antibodies and uses thereof
Polarized anti-VISTA antibodies address the challenge of VISTA's interaction in the tumor microenvironment by selectively binding at acidic pH, enhancing therapeutic efficacy and reducing drug depletion, thus improving cancer treatment outcomes.
Patent Information
- Application Number
- JP2024550123
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-09-21
- Filing Date
- 2022-11-09
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2042-11-09
AI Technical Summary
There is a need for therapeutic agents that target V-domain immunoglobulin inhibitor of T cell activation (VISTA), as its interaction with PSGL-1 is enhanced in the acidic tumor microenvironment, leading to cancer resistance to PD-1/PD-L1 inhibitors and challenges in achieving effective drug occupancy due to high expression on hematopoietic cells.
Development of pH-sensitive anti-VISTA antibodies that selectively bind to VISTA at acidic pH levels in the tumor microenvironment, inhibiting the VISTA-PSGL-1 interaction and overcoming target-mediated drug depletion, allowing for enhanced pharmacokinetic properties and broader therapeutic window.
The pH-sensitive anti-VISTA antibodies effectively inhibit VISTA in the tumor microenvironment, enhancing anti-tumor activity and reducing the risk of cytokine release syndrome, while maintaining efficacy and reducing frequency of administration.
Smart Images

Figure 2024543236000001_ABST
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Patent Application No. 63 / 277,395, filed November 9, 2021, U.S. Provisional Patent Application No. 63 / 332,813, filed April 20, 2022, U.S. Provisional Patent Application No. 63 / 374,147, filed August 31, 2022, and U.S. Provisional Patent Application No. 63 / 376,554, filed September 21, 2022, the disclosures of each of which are incorporated by reference in their entireties herein.
[0002] Electronic Sequence Listing Reference The contents of the electronic sequence listing (SEBI_024_001WO_SeqList_ST26.xml; size: 152,546 bytes; and creation date: November 7, 2022) are incorporated herein by reference in their entirety.
[0003] The present disclosure relates to therapeutic antibody molecules and their medical uses. [Background technology]
[0004] V-domain immunoglobulin inhibitor of T-cell activation (VISTA) is a type I transmembrane protein, a B7 family member that functions in immune regulation. VISTA is primarily expressed in hematopoietic cells and promotes T-cell and bone marrow quiescence. VISTA expression correlates with poor survival in multiple cancer indications. The interaction of VISTA with its receptor PSGL-1 was shown to be significantly enhanced by the acidic tumor microenvironment (TME) (Johnston et al. Nature 574,565-570(2019)). Therapeutics targeting VISTA are needed. Summary of the Invention
[0005] Provided herein are V domain immunoglobulin suppressor of anti-T cell activation (VISTA) antibodies, or antigen-binding portions thereof, comprising a heavy chain variable (VH) region and a light chain variable (VL) region, wherein (a) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO:54, an HCDR2 comprising SEQ ID NO:55, and an HCDR3 comprising SEQ ID NO:56, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO:57, an LCDR2 comprising SEQ ID NO:58, and an LCDR3 comprising SEQ ID NO:59, or (b) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO:60, an HCDR2 comprising SEQ ID NO:61, and an LCDR3 comprising SEQ ID NO:62. (c) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 62, HCDR2 comprising SEQ ID NO: 63 and HCDR3 comprising SEQ ID NO: 56, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 57, LCDR2 comprising SEQ ID NO: 58 and LCDR3 comprising SEQ ID NO: 59; or (d) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 62, HCDR2 comprising SEQ ID NO: 63 and HCDR3 comprising SEQ ID NO: 56, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 57, LCDR2 comprising SEQ ID NO: 58 and LCDR3 comprising SEQ ID NO: 59. (e) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 69, HCDR2 comprising SEQ ID NO: 70, and HCDR3 comprising SEQ ID NO: 56, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 57, LCDR2 comprising SEQ ID NO: 67, and LCDR3 comprising SEQ ID NO: 71; or (f) the VH region amino acid sequence comprises the sequence (g) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 73, HCDR2 comprising SEQ ID NO: 65, and HCDR3 comprising SEQ ID NO: 74, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 57, LCDR2 comprising SEQ ID NO: 58, and LCDR3 comprising SEQ ID NO: 71; or (h) the VH region amino acid sequence comprises(i) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 64, HCDR2 comprising SEQ ID NO: 65, and HCDR3 comprising SEQ ID NO: 77, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 57, LCDR2 comprising SEQ ID NO: 76, and LCDR3 comprising SEQ ID NO: 68; or (j) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 64, HCDR2 comprising SEQ ID NO: 65, and HCDR3 comprising SEQ ID NO: 77, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 57, LCDR2 comprising SEQ ID NO: 78, and LCDR3 comprising SEQ ID NO: 68. (k) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO:54, HCDR2 comprising SEQ ID NO:65 and HCDR3 comprising SEQ ID NO:79, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO:80, LCDR2 comprising SEQ ID NO:58 and LCDR3 comprising SEQ ID NO:68; or (l) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO:54, HCDR2 comprising SEQ ID NO:65 and HCDR3 comprising SEQ ID NO:79, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO:80, LCDR2 comprising SEQ ID NO:58 and LCDR3 comprising SEQ ID NO:68. (m) the amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 87, an HCDR2 comprising SEQ ID NO: 88, and an HCDR3 comprising SEQ ID NO: 83, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 84, an LCDR2 comprising SEQ ID NO: 85, and an LCDR3 comprising SEQ ID NO: 86; or (n) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 87, an HCDR2 comprising SEQ ID NO: 88, and an HCDR3 comprising SEQ ID NO: 83, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 84, an LCDR2 comprising SEQ ID NO: 85, and an LCDR3 comprising SEQ ID NO: 86. (o) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 91, an HCDR2 comprising SEQ ID NO: 92, and an HCDR3 comprising SEQ ID NO: 83, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 84, an LCDR2 comprising SEQ ID NO: 85, and an LCDR3 comprising SEQ ID NO: 86, or ...(p) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 93, HCDR2 comprising SEQ ID NO: 94, and HCDR3 comprising SEQ ID NO: 95, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 96, LCDR2 comprising SEQ ID NO: 85, and LCDR3 comprising SEQ ID NO: 97, or (q) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 98, HCDR2 comprising SEQ ID NO: 99, and HCDR3 comprising SEQ ID NO: 100, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 96, LCDR2 comprising SEQ ID NO: 101, and LCDR3 comprising SEQ ID NO: 102. 3, or (r) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 103, HCDR2 comprising SEQ ID NO: 104, and HCDR3 comprising SEQ ID NO: 105, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 96, LCDR2 comprising SEQ ID NO: 106, and LCDR3 comprising SEQ ID NO: 107, or (s) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 108, HCDR2 comprising SEQ ID NO: 94, and HCDR3 comprising SEQ ID NO: 105, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 109, LCDR2 comprising SEQ ID NO: 85, and LCDR3 comprising SEQ ID NO: (t) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 111, an HCDR2 comprising SEQ ID NO: 94, and an HCDR3 comprising SEQ ID NO: 112, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 96, an LCDR2 comprising SEQ ID NO: 85, and an LCDR3 comprising SEQ ID NO: 113, or (u) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 87, an HCDR2 comprising SEQ ID NO: 94, and an HCDR3 comprising SEQ ID NO: 114, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 115, an LCDR2 comprising SEQ ID NO: 85. (v) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 93, an HCDR2 comprising SEQ ID NO: 90, and an HCDR3 comprising SEQ ID NO: 117, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 118, an LCDR2 comprising SEQ ID NO: 85, and an LCDR3 comprising SEQ ID NO: 86, or (w) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 119, an HCDR2 comprising SEQ ID NO: 120, and an HCDR3 comprising SEQ ID NO: 121, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 57,or (x) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 123, an HCDR2 comprising SEQ ID NO: 124, and an HCDR3 comprising SEQ ID NO: 125, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 126, an LCDR2 comprising SEQ ID NO: 127, and an LCDR3 comprising SEQ ID NO: 128; or (y) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 123, an HCDR2 comprising SEQ ID NO: 124, and an HCDR3 comprising SEQ ID NO: 129, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 57, an LCDR2 comprising SEQ ID NO: 58, and an LCDR3 comprising SEQ ID NO: 130; or (z) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 131, an HCDR2 comprising SEQ ID NO: 132, and an HCDR3 comprising SEQ ID NO: 133, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 126, an LCDR2 comprising SEQ ID NO: 134, and an LCDR3 comprising SEQ ID NO: or (aa) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 131, an HCDR2 comprising SEQ ID NO: 132, and an HCDR3 comprising SEQ ID NO: 136, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 57, an LCDR2 comprising SEQ ID NO: 58, and an LCDR3 comprising SEQ ID NO: 137; or (bb) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 54, an HCDR2 comprising SEQ ID NO: 138, and an HCDR3 comprising SEQ ID NO: 139, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 57, an LCDR2 comprising SEQ ID NO: 58, and an LCDR3 comprising SEQ ID NO: 140; or (cc) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 81, an HCDR2 comprising SEQ ID NO: 82, and an HCDR3 comprising SEQ ID NO: 141, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 142, an LCDR2 comprising SEQ ID NO: 143, and an LCDR3 comprising SEQ ID NO: 144.
[0006] Provided herein are anti-VISTA antibodies, or antigen-binding portions thereof, comprising a VH region and a VL region, wherein (a) the VH region amino acid sequence comprises SEQ ID NO:1 and the VL region amino acid sequence comprises SEQ ID NO:2; (b) the VH region amino acid sequence comprises SEQ ID NO:3 and the VL region amino acid sequence comprises SEQ ID NO:2; (c) the VH region amino acid sequence comprises SEQ ID NO:4 and the VL region amino acid sequence comprises SEQ ID NO:2; (d) the VH region amino acid sequence comprises SEQ ID NO:5 and the VL region amino acid sequence comprises SEQ ID NO:6; or (e) the VH region (f) the VH region amino acid sequence comprises SEQ ID NO: 9 and the VL region amino acid sequence comprises SEQ ID NO: 10; (g) the VH region amino acid sequence comprises SEQ ID NO: 11 and the VL region amino acid sequence comprises SEQ ID NO: 12; (h) the VH region amino acid sequence comprises SEQ ID NO: 13 and the VL region amino acid sequence comprises SEQ ID NO: 14; (i) the VH region amino acid sequence comprises SEQ ID NO: 15 and the VL region amino acid sequence comprises SEQ ID NO: 16; or (j) the VH region amino acid sequence comprises SEQ ID NO: 17 and the VL region amino acid sequence comprises SEQ ID NO: 18. (k) the VH region amino acid sequence comprises SEQ ID NO:19 and the VL region amino acid sequence comprises SEQ ID NO:20; (l) the VH region amino acid sequence comprises SEQ ID NO:21 and the VL region amino acid sequence comprises SEQ ID NO:22; (m) the VH region amino acid sequence comprises SEQ ID NO:23 and the VL region amino acid sequence comprises SEQ ID NO:22; (n) the VH region amino acid sequence comprises SEQ ID NO:24 and the VL region amino acid sequence comprises SEQ ID NO:22; (o) the VH region amino acid sequence comprises SEQ ID NO:25 and the VL region amino acid sequence comprises SEQ ID NO:22; (p) the V (q) the VH region amino acid sequence comprises SEQ ID NO:28 and the VL region amino acid sequence comprises SEQ ID NO:29; (r) the VH region amino acid sequence comprises SEQ ID NO:30 and the VL region amino acid sequence comprises SEQ ID NO:31; (s) the VH region amino acid sequence comprises SEQ ID NO:32 and the VL region amino acid sequence comprises SEQ ID NO:33; (t) the VH region amino acid sequence comprises SEQ ID NO:34 and the VL region amino acid sequence comprises SEQ ID NO:35; or (u) the VH region amino acid sequence comprises SEQ ID NO:36;(v) the VH region amino acid sequence comprises SEQ ID NO:38 and the VL region amino acid sequence comprises SEQ ID NO:39; (w) the VH region amino acid sequence comprises SEQ ID NO:40 and the VL region amino acid sequence comprises SEQ ID NO:41; (x) the VH region amino acid sequence comprises SEQ ID NO:42 and the VL region amino acid sequence comprises SEQ ID NO:43; (y) the VH region amino acid sequence comprises SEQ ID NO:44 and the VL region amino acid sequence comprises SEQ ID NO:45; (z) the VH region amino acid sequence comprises SEQ ID NO:46 and the VL region amino acid sequence comprises SEQ ID NO:47; (aa) the VH region amino acid sequence comprises SEQ ID NO:48 and the VL region amino acid sequence comprises SEQ ID NO:49; (bb) the VH region amino acid sequence comprises SEQ ID NO:50 and the VL region amino acid sequence comprises SEQ ID NO:51; or (cc) the VH region amino acid sequence comprises SEQ ID NO:52 and the VL region amino acid sequence comprises SEQ ID NO:53.
[0007] In some embodiments, the antibody or antigen-binding portion is human or chimeric.
[0008] In some embodiments, the antibody or antigen-binding portion comprises an immunoglobulin constant region. In some embodiments, the immunoglobulin constant region is IgG, IgE, IgM, IgD, IgA, or IgY. In some embodiments, the immunoglobulin constant region is IgG1, IgG2, IgG3, IgG4, IgA1, or IgA2. In some embodiments, the immunoglobulin constant region is immunologically inert. In some embodiments, the immunoglobulin constant region is a wild-type human IgG4 constant region, a human IgG4 constant region comprising the amino acid substitution S228P, a wild-type human IgG1 constant region, a human IgG1 constant region comprising the amino acid substitutions L234A, L235A, and G237A, or a wild-type human IgG2 constant region, numbering according to the EU index as in Kabat. In some embodiments, the immunoglobulin constant region comprises any one of SEQ ID NOs: 145-149.
[0009] In some embodiments, the antibody or antigen-binding portion is a Fab, Fab', F(ab')2, Fv, scFv, maxibody, minibody, diabody, triabody, tetrabody, or bis-scFv.
[0010] In some embodiments, the antibody is monoclonal.
[0011] In some embodiments, the antibody or antigen-binding portion is a tetrameric antibody, tetravalent or multispecific, hi some embodiments, the antibody or antigen-binding portion is a bispecific antibody or antigen-binding portion that specifically binds to a first antigen and a second antigen, wherein the first antigen is VISTA and the second antigen is not VISTA.
[0012] Further provided herein is an immunoconjugate comprising an anti-VISTA antibody or antigen-binding portion disclosed herein linked to a therapeutic agent, in some embodiments the therapeutic agent is a cytotoxin, a radioisotope, a chemotherapeutic agent, an immunomodulatory agent, a cytostatic enzyme, a cytolytic enzyme, a therapeutic peptide, a therapeutic nucleic acid, an angiogenesis inhibitor, an anti-proliferative agent, or a pro-apoptotic agent.
[0013] Provided herein are pharmaceutical compositions comprising an anti-VISTA antibody, antigen-binding portion, or immunoconjugate disclosed herein, and a pharma- ceutically acceptable carrier, diluent, or excipient.
[0014] Further provided herein are nucleic acid molecules encoding (a) the VH region amino acid sequence, (b) the VL region amino acid sequence, or (c) both the VH region amino acid sequence and the VL region amino acid sequence of an anti-VISTA antibody or antigen-binding portion disclosed herein.
[0015] Provided herein is an expression vector comprising the nucleic acid molecule disclosed herein. Also provided herein is a recombinant host cell comprising the nucleic acid molecule or expression vector disclosed herein.
[0016] Further provided herein is a method of producing an anti-VISTA antibody, or antigen-binding portion thereof, comprising culturing a recombinant host cell containing an expression vector disclosed herein under conditions in which the nucleic acid molecule is expressed, thereby producing the antibody or antigen-binding portion, and isolating the antibody or antigen-binding portion from the host cell or culture.
[0017] Provided herein is a method for inducing an immune response in a subject, comprising administering to the subject a therapeutically effective amount of an anti-VISTA antibody or antigen-binding portion, immunoconjugate, or pharmaceutical composition disclosed herein. In some embodiments, the immune response is an immune response against cancer cells. In some embodiments, the immune response is antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, or antibody-dependent cellular phagocytosis.
[0018] Provided herein is a method for treating or preventing cancer in a subject, comprising administering to the subject a therapeutically effective amount of an anti-VISTA antibody or antigen-binding portion, immunoconjugate, or pharmaceutical composition disclosed herein. In some embodiments, the cancer is a hematological malignancy or epithelial cancer. In some embodiments, the cancer is squamous cell carcinoma of the head and neck, melanoma, non-small cell lung cancer, or colon cancer. In some embodiments, the cancer is acute myeloid leukemia (AML).
[0019] In some embodiments, the subject has VISTA overexpression. In some embodiments, the subject has VISTA overexpression in immune cells. In some embodiments, the immune cells are tumor infiltrating immune cells. In some embodiments, the immune cells are bone marrow cells or monocytes.
[0020] In some embodiments, the methods disclosed herein further comprise administering to the subject an inhibitor of PD-1 or an inhibitor of PD-L1. In some embodiments, the inhibitor of PD-1 is an anti-PD-1 antibody, or an antigen-binding portion thereof. In some embodiments, the inhibitor of PD-L1 is an anti-PD-L1 antibody, or an antigen-binding portion thereof.
[0021] Provided herein is an anti-VISTA antibody or antigen-binding portion, immunoconjugate, or pharmaceutical composition disclosed herein for use as a medicament.
[0022] Provided herein are methods for treating a tumor in a subject, the methods comprising: (a) obtaining a VISTA:PSGL-1 proximity score for a tumor specimen from a subject, (i) obtaining images of tissues excised from a tumor specimen and immunohistochemically stained for VISTA and PSGL-1 expression in such a manner that VISTA stained cells can be distinguished from PSGL-1 stained cells; (ii) defining one or more regions of interest (ROIs) in the image that include tumor cells and tumor stroma, wherein substantially all of the tumor cells and tumor stroma in the image are contained within the defined ROIs; (iii) randomly creating a plurality of sub-regions of substantially the same shape and size across each defined ROI, each of the sub-regions defining an area large enough to include pairs of stained VISTA and PSGL-1 cells that are spatially proximal, and small enough to exclude pairs of stained VISTA and PSGL-1 cells that are not spatially proximal; and (iv) assigning or obtaining a VISTA:PSGL-1 proximity score to the tumor specimen by a step comprising: calculating the percentage of all sub-areas that are positive for both VISTA stained cells and PSGL-1 stained cells to generate a VISTA:PSGL-1 proximity score for the tumor specimen; (b) comparing the VISTA:PSGL-1 proximity score of the tumor specimen with a threshold VISTA:PSGL-1 proximity score; (c) classifying the tumor as biomarker positive or biomarker negative, where if the tumor specimen has a proximity score equal to or greater than the threshold proximity score, the tumor is classified as VISTA:PSGL-1 proximal biomarker positive, and if the tumor specimen has a score less than the threshold score, the tumor is classified as VISTA:PSGL-1 proximal biomarker negative; and (d) if the tumor is positive for the VISTA:PSGL-1 proximity biomarker, administering to the subject a therapeutically effective amount of an anti-VISTA antibody or antigen-binding portion, immunoconjugate, or pharmaceutical composition disclosed herein. [Brief description of the drawings]
[0023] [Figure 1] Schematic diagram of the strategy implemented for primary selection of pH-dependent anti-VISTA antibodies. Selection rounds are indicated with "R". MACS = magnetic activated cell sorting. FACS = fluorescence activated cell sorting. [Diagram 2] FIG. 1 shows a schematic diagram of the steps taken in the discovery of parent anti-VISTA antibodies. [Diagram 3] Figure 1 shows the results of a study of the binding properties of an exemplary anti-VISTA antibody. Avidity and monovalent affinity measurements at pH 7.4 and pH 6.0 were measured by Octet. Binding profiles of anti-VISTA mAbs on CHO-VISTA (VISTA overexpressing) and KASUMI-3 (endogenous VISTA) cells are shown. FOB = fold over background. [Figure 4A] Figure 1 shows the results of a study of the inhibitory properties of anti-VISTA antibodies. VISTA-dextramer-PE interacts with PSGL-1 on primary T cells at pH 6.0. [Figure 4B] 1 shows the results of a study of the inhibitory properties of anti-VISTA antibodies. Anti-VISTA mAb #2 inhibits VISTA:PSGL-1 interaction in CD4 and CD8 T cells. [Figure 4C] Figure 1 shows the results of a study of the inhibitory characteristics of anti-VISTA antibodies. The top 8 anti-VISTA mAbs ranked by PSGL-1:VISTA competitive ELISA are shown. [Figure 5A] Figure 1 shows the results of a study of tumor growth inhibition of MC38 in human VISTA knock-in mice. Black line (human and rat IgG control), dark grey line (human IgG control and rat anti-mPD-1, light grey line (rat anti-mPD-1 and anti-VISTA). CR = complete response. [Figure 5B] Figure 1 shows the results of a study of tumor growth inhibition of MC38 in human VISTA knock-in mice. Black line (human and rat IgG control), dark grey line (human IgG control and rat anti-mPD-1, light grey line (rat anti-mPD-1 and anti-VISTA). CR = complete response. [Figure 5C] Figure 1 shows the results of a study of tumor growth inhibition of MC38 in human VISTA knock-in mice. Black line (human and rat IgG control), dark grey line (human IgG control and rat anti-mPD-1, light grey line (rat anti-mPD-1 and anti-VISTA). CR = complete response. [Figure 5D] Figure 1 shows the results of a study of tumor growth inhibition of MC38 in human VISTA knock-in mice. Black line (human and rat IgG control), dark grey line (human IgG control and rat anti-mPD-1, light grey line (rat anti-mPD-1 and anti-VISTA). CR = complete response. [Figure 5E] Figure 1 shows the results of a study of tumor growth inhibition of MC38 in human VISTA knock-in mice. Black line (human and rat IgG control), dark grey line (human IgG control and rat anti-mPD-1, light grey line (rat anti-mPD-1 and anti-VISTA). CR = complete response. [Figure 5F] Figure 1 shows the results of a study of tumor growth inhibition of MC38 in human VISTA knock-in mice. Black line (human and rat IgG control), dark grey line (human IgG control and rat anti-mPD-1, light grey line (rat anti-mPD-1 and anti-VISTA). CR = complete response. [Figure 5G] Figure 1 shows the results of a study of tumor growth inhibition of MC38 in human VISTA knock-in mice. Black line (human and rat IgG control), dark grey line (human IgG control and rat anti-mPD-1, light grey line (rat anti-mPD-1 and anti-VISTA). CR = complete response. [Figure 5H] Figure 1 shows the results of a study of tumor growth inhibition of MC38 in human VISTA knock-in mice. Black line (human and rat IgG control), dark grey line (human IgG control and rat anti-mPD-1, light grey line (rat anti-mPD-1 and anti-VISTA). CR = complete response. [Figure 6] A schematic diagram of the steps performed for lead optimization of the top eight parent anti-VISTA antibodies is shown. [Figure 7A] Figure 7 shows the results of a study characterizing optimized progeny anti-VISTA antibodies. Binding profiles of two representative anti-VISTA parent antibodies and their respective progeny on KASUMI-3 cells at pH 6.0 and pH 7.4 (Figure 7A). Binding profile of SNS-101 (Fab on CHO-VISTA cells), inhibitory function and characterization by SPR (Figures 7B, 7C and 7D). For SPR, identical concentrations of monomeric VISTA were passed over the antibody immobilized on Protein A surface at pH 6.0 or 7.4. RU = response units; NB = non-bound; FOB = fold over background. [Figure 7B] Figure 7 shows the results of a study characterizing optimized progeny anti-VISTA antibodies. Binding profiles of two representative anti-VISTA parent antibodies and their respective progeny on KASUMI-3 cells at pH 6.0 and pH 7.4 (Figure 7A). Binding profile of SNS-101 (Fab on CHO-VISTA cells), inhibitory function and characterization by SPR (Figures 7B, 7C and 7D). For SPR, identical concentrations of monomeric VISTA were passed over the antibody immobilized on Protein A surface at pH 6.0 or 7.4. RU = response units; NB = non-bound; FOB = fold over background. [Figure 7C]Figure 7 shows the results of a study characterizing optimized progeny anti-VISTA antibodies. Binding profiles of two representative anti-VISTA parent antibodies and their respective progeny on KASUMI-3 cells at pH 6.0 and pH 7.4 (Figure 7A). Binding profile of SNS-101 (Fab on CHO-VISTA cells), inhibitory function and characterization by SPR (Figures 7B, 7C and 7D). For SPR, identical concentrations of monomeric VISTA were passed over the antibody immobilized on Protein A surface at pH 6.0 or 7.4. RU = response units; NB = non-bound; FOB = fold over background. [Figure 7D] Figure 7 shows the results of a study characterizing optimized progeny anti-VISTA antibodies. Binding profiles of two representative anti-VISTA parent antibodies and their respective progeny on KASUMI-3 cells at pH 6.0 and pH 7.4 (Figure 7A). Binding profile of SNS-101 (Fab on CHO-VISTA cells), inhibitory function and characterization by SPR (Figures 7B, 7C and 7D). For SPR, identical concentrations of monomeric VISTA were passed over the antibody immobilized on Protein A surface at pH 6.0 or 7.4. RU = response units; NB = non-bound; FOB = fold over background. [Figure 8A] 1 shows the results of an in vivo study of the activity of anti-VISTA antibodies. Effect on tumor volume over time is shown. Black line (human and rat IgG control), dark grey line (human IgG control and rat anti-mPD-1, light grey line (rat anti-mPD-1 and anti-VISTA). [Figure 8B] 1 shows the results of an in vivo study of the activity of anti-VISTA antibodies. Effect on percent survival over time is shown. Black line (human and rat IgG control), dark grey line (human IgG control and rat anti-mPD-1, light grey line (rat anti-mPD-1 and anti-VISTA). [Figure 9A] Images and data analysis results of a multiplex immunohistochemistry assay to quantify the spatial proximity of VISTA+ and PSGL-1+ cells are shown. 5VISTA_1 Tonsil (QC19-14). [Figure 9B]Images and data analysis results of a multiplex immunohistochemistry assay to quantify the spatial proximity of VISTA+ and PSGL-1+ cells are shown. :5VISTA_1 Tonsil (QC19-14). [Figure 9C] Images and data analysis results of a multiplex immunohistochemistry assay to quantify the spatial proximity of VISTA+ and PSGL-1+ cells are shown. :5VISTA_1 H&N(010-001). [Figure 9D] Images and data analysis results of a multiplex immunohistochemistry assay to quantify the spatial proximity of VISTA+ and PSGL-1+ cells are shown. H&N (HN483a) Core C6, R7. [Figure 9E] 1 shows images and data analysis results of a multiplex immunohistochemistry assay to quantify the spatial proximity of VISTA+ and PSGL-1+ cells. [Figure 9F] 1 shows images and data analysis results of a multiplex immunohistochemistry assay to quantify the spatial proximity of VISTA+ and PSGL-1+ cells. Spatial Analysis H&N (HN83a) Core C6, R7. [Figure 9G] Images and data analysis results of a multiplex immunohistochemistry assay to quantify the spatial proximity of VISTA+ and PSGL-1+ cells are shown. H&N (HN483a) Core C5, R4. [Figure 9H] 1 shows images and data analysis results of a multiplex immunohistochemistry assay to quantify the spatial proximity of VISTA+ and PSGL-1+ cells. [Figure 9I] 1 shows the results of image and data analysis of a multiplex immunohistochemistry assay to quantify the spatial proximity of VISTA+ and PSGL-1+ cells. Spatial Analysis H&N (HN83a) Core C5, R4. [Figure 9J] Images and data analysis results of a multiplex immunohistochemistry assay to quantify the spatial proximity of VISTA+ and PSGL-1+ cells. BrCA(BR1202a)Core C4, R9. [Figure 9K] Images and data analysis results of a multiplex immunohistochemistry assay to quantify the spatial proximity of VISTA+ and PSGL-1+ cells. BrCA(BR1202a)Core C9, R5. [Figure 9L] Images and data analysis results of a multiplex immunohistochemistry assay to quantify the spatial proximity of VISTA+ and PSGL-1+ cells are shown. CRC (BC05012a) Core C5, R4. [Figure 10A] Cytokine release profile assay of SNS-101 in an ex vivo system mimicking human blood circulation. IFN-γ. JNJ: Antibody JNJ-61610588 variable regions cloned onto a human IgG1 backbone. [Figure 10B] Cytokine release profile assay of SNS-101 in an ex vivo system mimicking human blood circulation. IL-6. JNJ: Antibody JNJ-61610588 variable regions cloned onto a human IgG1 backbone. [Figure 10C] Cytokine release profile assay of SNS-101 in an ex vivo system mimicking human blood circulation. IL-8. JNJ: Antibody JNJ-61610588 variable regions cloned onto a human IgG1 backbone. [Figure 10D] Cytokine release profile assay of SNS-101 in an ex vivo system mimicking human blood circulation. TNF-α. JNJ: Antibody JNJ-61610588 variable regions cloned onto a human IgG1 backbone. [Figure 10E] Cytokine release profile assay of SNS-101 in an ex vivo system mimicking human blood circulation. IL-2. JNJ: Antibody JNJ-61610588 variable regions cloned onto a human IgG1 backbone. [Figure 10F]Flow cytometry analysis of SNS-101 activation of human monocytes and natural killer (NK) cells. Percentage of CD83+ monocytes is shown. JNJ: antibody JNJ-61610588 variable regions cloned onto a human IgG1 backbone. [Figure 10G] Flow cytometry analysis of SNS-101 activation of human monocytes and natural killer (NK) cells. Percentage of CD83 MFI (median) is shown. JNJ: antibody JNJ-61610588 variable region cloned onto a human IgG1 backbone. MFI: median fluorescence intensity. [Figure 10H] Flow cytometry analysis of SNS-101 activation of human monocytes and natural killer (NK) cells. Percentage of CD69+ NK cells is shown. JNJ: antibody JNJ-61610588 variable regions cloned onto a human IgG1 backbone. [Figure 10I] Flow cytometry analysis of SNS-101 activation of human monocytes and natural killer (NK) cells. Percentages of CD69 MFI (median) are shown. JNJ: antibody JNJ-61610588 variable region cloned onto a human IgG1 backbone. MFI: median fluorescence intensity. [Figure 11A] Figure 11 shows the results of pharmacokinetic (PK) profiling of pH-sensitive anti-VISTA antibody SNS-101 in cynomolgus monkeys. Figure 11A shows the PK profile of SNS-101, which shows linear elimination kinetics, and the PK profile of non-pH-selective antibody h26A, which shows TMDD and rapid clearance. Analysis of the data from Figure 11A yields the plasma CL, T1 / 2λ and VSS of SNS-101 for doses of 1 mg / kg, 10 mg / kg and 100 mg / kg, as shown in Figure 11B. [Figure 11B]Figure 11 shows the results of pharmacokinetic (PK) profiling of pH-sensitive anti-VISTA antibody SNS-101 in cynomolgus monkeys. Figure 11A shows the PK profile of SNS-101, which shows linear elimination kinetics, and the PK profile of non-pH-selective antibody h26A, which shows TMDD and rapid clearance. Analysis of the data from Figure 11A yields the plasma CL, T1 / 2λ and VSS of SNS-101 for doses of 1 mg / kg, 10 mg / kg and 100 mg / kg, as shown in Figure 11B. [Figure 12A] Results from studies in the MC-38 model of human VISTA knock-in mice are shown, demonstrating that SNS-101 exhibits robust activity in combination with anti-PD-1 antibodies to increase the amount of CD8+ T cells. The effect on tumor volume is shown. The following treatment groups were tested: [Figure 12B] Figure 1 shows results from a study in the MC-38 model of human VISTA knock-in mice, demonstrating that SNS-101 exhibits robust activity in combination with anti-PD-1 antibodies to increase the amount of CD8+ T cells. The frequency of CD8+ cells determined in a single live CD45+ population by analytical flow cytometry analysis is shown. The following treatment groups were tested: 1: isotype control. 2: 1 mg / kg αPD-1. 3: 10 mg / kg SNS-101. 4: 30 mg / kg SNS-101. 5: 1 mg / kg αPD-1 + 10 mg / kg SNS-101. 6: 1 mg / kg αPD-1 + 30 mg / kg SNS-101. [Figure 12C]Figure 1 shows results from a study in the MC-38 model of human VISTA knock-in mice, showing that SNS-101 exhibits robust activity in combination with anti-PD-1 antibodies to increase the amount of CD8+ T cells. Figure 2 shows a heat map of relative cytokine levels across different treatment groups from the study. The following treatment groups were tested: 1: isotype control. 2: 1 mg / kg αPD-1. 3: 10 mg / kg SNS-101. 4: 30 mg / kg SNS-101. 5: 1 mg / kg αPD-1 + 10 mg / kg SNS-101. 6: 1 mg / kg αPD-1 + 30 mg / kg SNS-101. Scaled group mean cytokine levels (z-scores of log-transformed data) were used to generate the heat map. Cytokines were aligned by hierarchical clustering with Euclidean distance for the cytokine profile. [Figure 12D] Figure 12 shows the results of a study in the MB49 syngeneic tumor model in human VISTA knock-in mice. Mice were treated with either 1 mg / kg and 5 mg / kg of anti-mouse PD-1 antibody (RMP1-14) alone or in combination with 3 mg / kg, 10 mg / kg, and 30 mg / kg of SNS-101-m2, respectively. The effect on tumor volume is shown for individual mice (Figures 12D and 12E) and for the combined treatment groups (Figures 12F and 12G). Groups were treated with (1) mouse and rat IgG control (control), (2) IgG control mouse and rat anti-mPD-1, or (3) rat anti-mPD-1 and anti-VISTA. Figure 12H shows a heat map of relative cytokine levels across the different treatment groups from the study. The following treatment groups were tested: 1: Isotype control. 1: αPD-1 at 1 mg / kg. 2: αPD-1 at 1 mg / kg. 3: αPD-1 at 5 mg / kg. 4: SNS-101 at 3 mg / kg. 5: αPD-1 at 1 mg / kg + SNS-101 at 3 mg / kg. 6: αPD-1 at 5 mg / kg + SNS-101 at 3 mg / kg. Heatmaps were generated using scaled group mean cytokine levels (z-scores of log-transformed data). Cytokines were aligned by hierarchical clustering with Euclidean distance for cytokine profiles. [Figure 12E]Figure 12 shows the results of a study in the MB49 syngeneic tumor model in human VISTA knock-in mice. Mice were treated with either 1 mg / kg and 5 mg / kg of anti-mouse PD-1 antibody (RMP1-14) alone or in combination with 3 mg / kg, 10 mg / kg, and 30 mg / kg of SNS-101-m2, respectively. The effect on tumor volume is shown for individual mice (Figures 12D and 12E) and for the combined treatment groups (Figures 12F and 12G). Groups were treated with (1) mouse and rat IgG control (control), (2) IgG control mouse and rat anti-mPD-1, or (3) rat anti-mPD-1 and anti-VISTA. Figure 12H shows a heat map of relative cytokine levels across the different treatment groups from the study. The following treatment groups were tested: 1: Isotype control. 1: αPD-1 at 1 mg / kg. 2: αPD-1 at 1 mg / kg. 3: αPD-1 at 5 mg / kg. 4: SNS-101 at 3 mg / kg. 5: αPD-1 at 1 mg / kg + SNS-101 at 3 mg / kg. 6: αPD-1 at 5 mg / kg + SNS-101 at 3 mg / kg. Heatmaps were generated using scaled group mean cytokine levels (z-scores of log-transformed data). Cytokines were aligned by hierarchical clustering with Euclidean distance for cytokine profiles. [Figure 12F]Figure 12 shows the results of a study in the MB49 syngeneic tumor model in human VISTA knock-in mice. Mice were treated with either 1 mg / kg and 5 mg / kg of anti-mouse PD-1 antibody (RMP1-14) alone or in combination with 3 mg / kg, 10 mg / kg, and 30 mg / kg of SNS-101-m2, respectively. The effect on tumor volume is shown for individual mice (Figures 12D and 12E) and for the combined treatment groups (Figures 12F and 12G). Groups were treated with (1) mouse and rat IgG control (control), (2) IgG control mouse and rat anti-mPD-1, or (3) rat anti-mPD-1 and anti-VISTA. Figure 12H shows a heat map of relative cytokine levels across the different treatment groups from the study. The following treatment groups were tested: 1: Isotype control. 1: αPD-1 at 1 mg / kg. 2: αPD-1 at 1 mg / kg. 3: αPD-1 at 5 mg / kg. 4: SNS-101 at 3 mg / kg. 5: αPD-1 at 1 mg / kg + SNS-101 at 3 mg / kg. 6: αPD-1 at 5 mg / kg + SNS-101 at 3 mg / kg. Heatmaps were generated using scaled group mean cytokine levels (z-scores of log-transformed data). Cytokines were aligned by hierarchical clustering with Euclidean distance for cytokine profiles. [Figure 12G]Figure 12 shows the results of a study in the MB49 syngeneic tumor model in human VISTA knock-in mice. Mice were treated with either 1 mg / kg and 5 mg / kg of anti-mouse PD-1 antibody (RMP1-14) alone or in combination with 3 mg / kg, 10 mg / kg, and 30 mg / kg of SNS-101-m2, respectively. The effect on tumor volume is shown for individual mice (Figures 12D and 12E) and for the combined treatment groups (Figures 12F and 12G). Groups were treated with (1) mouse and rat IgG control (control), (2) IgG control mouse and rat anti-mPD-1, or (3) rat anti-mPD-1 and anti-VISTA. Figure 12H shows a heat map of relative cytokine levels across the different treatment groups from the study. The following treatment groups were tested: 1: Isotype control. 1: αPD-1 at 1 mg / kg. 2: αPD-1 at 1 mg / kg. 3: αPD-1 at 5 mg / kg. 4: SNS-101 at 3 mg / kg. 5: αPD-1 at 1 mg / kg + SNS-101 at 3 mg / kg. 6: αPD-1 at 5 mg / kg + SNS-101 at 3 mg / kg. Heatmaps were generated using scaled group mean cytokine levels (z-scores of log-transformed data). Cytokines were aligned by hierarchical clustering with Euclidean distance for cytokine profiles. [Figure 12H]Figure 12 shows the results of a study in the MB49 syngeneic tumor model in human VISTA knock-in mice. Mice were treated with either 1 mg / kg and 5 mg / kg of anti-mouse PD-1 antibody (RMP1-14) alone or in combination with 3 mg / kg, 10 mg / kg, and 30 mg / kg of SNS-101-m2, respectively. The effect on tumor volume is shown for individual mice (Figures 12D and 12E) and for the combined treatment groups (Figures 12F and 12G). Groups were treated with (1) mouse and rat IgG control (control), (2) IgG control mouse and rat anti-mPD-1, or (3) rat anti-mPD-1 and anti-VISTA. Figure 12H shows a heat map of relative cytokine levels across the different treatment groups from the study. The following treatment groups were tested: 1: Isotype control. 1: αPD-1 at 1 mg / kg. 2: αPD-1 at 1 mg / kg. 3: αPD-1 at 5 mg / kg. 4: SNS-101 at 3 mg / kg. 5: αPD-1 at 1 mg / kg + SNS-101 at 3 mg / kg. 6: αPD-1 at 5 mg / kg + SNS-101 at 3 mg / kg. Heatmaps were generated using scaled group mean cytokine levels (z-scores of log-transformed data). Cytokines were aligned by hierarchical clustering with Euclidean distance for cytokine profiles. [Figure 13] Figure 1 shows the results of an in vivo cytokine release profile assay of SNS-101 in a cytokine release syndrome mouse model. JNJ: JNJ: antibody JNJ-61610588 variable regions cloned onto a human IgG1 backbone. OKT3: positive control anti-CD3 antibody. Dotted line = limit of detection. [Figure 14A] Shown is an image of the putative SNS-101 (grey):VISTA binding interface (defined by peptide array (PepScan) binding) aligned to the positions of the five key His residues involved in PSGL-1 (dark grey) binding. [Figure 14B] Shown is an image of residues proposed to be involved in binding to putative partners VSIG-3 (light grey) and LRIG-1 (medium grey) aligned with the positions of the five key His residues involved in PSGL-1 (dark grey) binding. [Figure 14C]Crystal structure of hVISTA:SNS101_Fab complex. hVISTA is represented as a molecular surface and SNS101_Fab is represented as a ribbon cartoon. The blocked surface of VISTA in the presence of SNS-101 is shaded in light grey, while the unblocked portion is shaded in dark grey. The dark and light grey shaded ribbons represent the light and heavy chains of SNS-101_Fab, respectively. All amino acids of hVISTA that are within 4 Å of any portion of SNS-101 were used to create the blocked surface. [Figure 14D] Crystal structure of hVISTA:SNS101_Fab complex. hVISTA is represented as a molecular surface and SNS101_Fab is represented as a ribbon cartoon. The blocked surface of VISTA in the presence of SNS-101 is shaded in light grey, while the unblocked portion is shaded in dark grey. The dark and light grey shaded ribbons represent the light and heavy chains of SNS-101_Fab, respectively. All amino acids of hVISTA that are within 4 Å of any portion of SNS-101 were used to create the blocked surface. [Figure 14E] Crystal structure of hVISTA:SNS101_Fab complex. hVISTA is represented as a molecular surface and SNS101_Fab is represented as a ribbon cartoon. The blocked surface of VISTA in the presence of SNS-101 is shaded in light grey and the unblocked portion is shaded in dark grey. The dark and light grey shaded ribbons represent the light and heavy chains of SNS-101_Fab, respectively. All amino acids of hVISTA that are within 6 Å (Figure 14E,F) of any part of SNS-101 were used to create the blocked surface. [Figure 14F]Crystal structure of hVISTA:SNS101_Fab complex. hVISTA is represented as a molecular surface and SNS101_Fab is represented as a ribbon cartoon. The blocked surface of VISTA in the presence of SNS-101 is shaded in light grey and the unblocked portion is shaded in dark grey. The dark and light grey shaded ribbons represent the light and heavy chains of SNS-101_Fab, respectively. All amino acids of hVISTA that are within 6 Å (Figure 14E,F) of any part of SNS-101 were used to create the blocked surface. [Figure 14G] The interacting amino acids of PSGL-1, VSIG-3 and LRIG-1 are highlighted on the hVISTA structure. PSGL-1: black (His153 / 154 / 155 / 98 / 100). VSIG-3: dark grey (Phe94 / Gln95 / Arg86). LRIG-1: medium grey (Thr82 / Arg87). hVISTA-light grey. [Figure 15] Shown are the results of competition experiments using dilutions of SNS-101 or isotype controls, other potential VISTA binding partners and biotinylated hVISTA-Fc. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0024] Provided herein are anti-VISTA antibodies and therapeutic uses of such antibodies. The antibodies disclosed herein inhibit the interaction of VISTA with its receptor PSGL-1 (P-selectin glycoprotein ligand-1).
[0025] V-domain immunoglobulin inhibitor of T-cell activation (VISTA; also known as c10orf54, VSIR, SISP1, B7-H5, PD-1H, DD1α, Gi24, and Dies1) is a type I transmembrane protein consisting of a single N-terminal immunoglobulin (Ig) V-domain, an approximately 30 amino acid (aa) stalk, a transmembrane domain, and an approximately 95 amino acid intracytoplasmic tail. VISTA is an inhibitory B7 family immune checkpoint protein that is a negative regulator of T-cell function. VISTA is constitutively expressed on multiple immune cell types.
[0026] VISTA is highly expressed in bone marrow cells, including blood cells, and is therefore expressed at physiological pH of 7.4 (VISTA ppH Antibodies that bind VISTA at the 5'-terminal end of the VISTA domain may result in rapid elimination from the circulation via target-mediated drug elimination (TMDD), which may make it difficult to reach effective drug occupancy levels and narrow the therapeutic window. Provided herein are anti-VISTA antibodies that exhibit pH-sensitive inhibitory VISTA association. Such antibodies have enhanced pharmacokinetic properties, allowing for less frequent dosing. These antibodies also provide a broader therapeutic window. In some aspects, the anti-VISTA antibodies provided herein are pH-selective, inhibitory, high affinity, and cross-reactive with cynomolgus VISTA. In some aspects, the anti-VISTA antibodies provided herein exhibit combinability with anti-PD-1 inhibitors, resulting in superior anti-tumor activity. VISTA has been implicated in cancer resistance to PD-1 / PD-L1 inhibitors, so an anti-VISTA antibody that is compatible with PD-1 / PD-L1 blockade would be advantageous. In some embodiments, the antibodies provided herein have a low risk of inducing cytokine release syndrome (CRS). The antibodies provided herein are capable of preventing on-target, off-tumor VISTA binding that can induce CRS in human patients.
[0027] antibody Provided herein are antibodies and antigen-binding portions thereof that specifically bind to VISTA. The development of therapeutics targeting VISTA has been hindered by the presence of a pharmacological "sink" due to the high expression of VISTA on hematopoietic (blood) cells. Furthermore, VISTA has been shown to bind to its receptor (PSGL-1) on T cells at a pH (about 6) below physiological pH. The anti-VISTA antibodies and antigen-binding portions provided herein exhibit pH-selective binding behavior for VISTA, thus alleviating TMDD. In some embodiments, the antibodies provided herein bind to VISTA only at an acidic pH (about pH 6) found in the tumor microenvironment, which is lower than blood pH levels (pH 7.4), allowing for selective inhibition of VISTA in tumors.
[0028] The antibodies and antigen-binding portions disclosed herein specifically bind human VISTA. In some embodiments, the antibodies and antigen-binding portions may cross-react with VISTA from species other than human, such as Macaca fascicularis VISTA. In some embodiments, the antibodies may be specific only for human VISTA and may not exhibit cross-reactivity with non-humans. Exemplary amino acid sequences of human and cynomolgus VISTA are set forth in Table 31.
[0029] The term "antibody" refers broadly to an immunoglobulin (Ig) molecule, generally comprising four polypeptide chains, two heavy (H) chains and two light (L) chains, or any functional fragment, mutant, variant, or derivative thereof that retains the essential target-binding characteristics of an Ig molecule. Such mutant, variant, or derivative antibody formats are known in the art.
[0030] In a full-length antibody, each heavy chain comprises a heavy chain variable region (abbreviated herein as VH region) and a heavy chain constant region. The heavy chain constant region comprises three domains: CH1, CH2, and CH3. Each light chain comprises a light chain variable region (abbreviated herein as VL region) and a light chain constant region. The light chain constant region comprises one domain, CL. The VH and VL regions can be further subdivided into regions of hypervariability called complementarity determining regions (CDRs), interspersed with more conserved regions called framework regions (FRs). Each of the VH and VL domains is composed of three CDRs and four FRs, arranged from the amino terminus to the carboxy terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
[0031] The term "Fc region" is used to define the C-terminal region of an immunoglobulin heavy chain. An "Fc region" may be a native sequence Fc region or a variant Fc region. Although the boundaries of the Fc region of an immunoglobulin heavy chain may vary, the human IgG heavy chain Fc region is usually defined as the region from the amino acid residue at position Cys226, or from Pro230, to its carboxyl terminus. The numbering of residues in the Fc region is according to the EU index, similar to Kabat. The Fc region of an immunoglobulin generally contains two constant domains, CH2 and CH3. The Fc region may exist in either dimeric or monomeric forms. The Fc region binds to various cellular receptors, e.g., Fc receptors, and other immune molecules, e.g., complement proteins.
[0032] Immunoglobulin molecules can be of any type (e.g., IgG, IgE, IgM, IgD, IgA or IgY) and class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 or IgA2) or subclass. IgG, IgD and IgE antibodies generally contain two identical heavy chains and two identical light chains and two antigen-binding domains, each composed of a VH and a VL. IgA antibodies are generally composed of two monomers, each composed of two heavy chains and two light chains (as in IgG, IgD and IgE antibodies), in which the IgA molecule has four antigen-binding domains, each also composed of a VH and a VL. Certain IgA antibodies are monomers composed of two heavy chains and two light chains. Secretory IgM antibodies are generally composed of five monomers, each of which is composed of two heavy chains and two light chains (as in IgG and IgE antibodies). Thus, an IgM molecule has 10 antigen-binding domains, each of which is also composed of a VH and a VL. Cell surface forms of IgM have a two heavy / two light chain structure similar to IgG, IgD and IgE antibodies.
[0033] The term "antigen-binding portion" or "antigen-binding fragment" of an antibody (or "antibody portion" or "antibody fragment"), as used herein, refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen (e.g., VISTA). It has been shown that the antigen-binding function of an antibody can be performed by portions or fragments of a full-length antibody. Examples of binding moieties encompassed within the term "antigen-binding portion" of an antibody include (i) a Fab fragment, which is a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) a F(ab')2 fragment, which is a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) an Fd fragment consisting of the VH and CH1 domains; (iv) an Fv fragment consisting of the VL and VH domains of a single arm of an antibody; (v) a dAb (domain antibody) fragment comprising a single variable domain (Ward et al., (1989) Nature 341:544-546; WO90 / 05144 A1, each of which is incorporated herein by reference in its entirety); and (vi) an isolated complementarity determining region (CDR). The present disclosure also encompasses Fab' fragments. Fab' fragments can be formed by reduction of F(ab')2 fragments. Fab' is derived from F(ab')2 and therefore may contain a small Fc portion. Furthermore, although the two domains of the Fv fragment, VL and VH, are encoded by separate genes, they can be linked using recombinant methods by a synthetic linker that allows them to be produced as a single protein chain, with the VL and VH domains pairing to form a monovalent molecule (known as single chain Fv (scFv)). See, e.g., Bird et al. (1988) Science 242:423-426, Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883. Such single chain antibodies are also intended to be encompassed within the term "antigen-binding portion" of an antibody. In some embodiments, scFv molecules may be incorporated into fusion proteins. In some embodiments, single chain camelid antibodies are provided herein. In some embodiments, shark heavy chain antibodies (V-NARs) are provided herein.See English et al. (2020) Antibody Therapeutics, 3(1):1-9. Examples of antigen-binding moieties are known in the art (Kontermann and Dubel eds., Antibody Engineering (2001) Springer-Verlag. New York. 790 pp.). In some embodiments, single domain antibodies are provided herein. In general, the term "antibody" as used herein encompasses "antibody portions." Antibody portions generally retain the antigen-binding properties of full-length antibodies.
[0034] The antibodies and antibody portions provided herein may be in a multispecific (e.g., bispecific or trispecific) format. Such multispecific molecules specifically bind to two or more different molecular targets or epitopes. In some embodiments, the antibodies or antigen-binding portions provided herein are tetrameric, tetravalent, or multispecific. In some embodiments, the antibodies or antigen-binding portions are bispecific molecules that specifically bind to a first antigen and a second antigen, where the first antigen is VISTA and the second antigen is not VISTA. In some embodiments, the antibodies or antigen-binding portions are diabodies. Diabodies are bivalent, bispecific antibodies in which the VH and VL domains are expressed on a single polypeptide chain, but with a linker that is too short for the two domains on the same chain to pair, thereby forcing them to pair with complementary domains on another chain and generating two antigen-binding sites (see, e.g., Holliger et al. (1993) Proc. Natl. Acad. Sci. USA 90:6444-6448; Poljak et al. (1994) Structure 2:1121-1123). In some embodiments, the antibody or antigen-binding portion is a triabody, tetrabody, bis-scFv, or tandem scFv. In some embodiments, the antibody or antigen-binding portion is a dual affinity re-targeting protein.
[0035] In some embodiments, an anti-VISTA antibody or antigen-binding portion disclosed herein is a Fab, Fab', F(ab')2, Fv, scFv, maxibody, minibody, diabody, triabody, tetrabody, or bis-scFv.
[0036] As used herein, the terms "immunological binding" and "immunological binding properties" refer to the types of non-covalent interactions that occur between an immunoglobulin molecule (e.g., an antibody or antigen-binding portion thereof) and an antigen for which the immunoglobulin is specific. The strength, or affinity, of an immunological binding interaction is determined by the dissociation constant (K d ), and K d A smaller K represents a greater affinity. The immunological binding properties of a selected polypeptide can be quantified using methods well known in the art. One such method involves measuring the rates of formation and dissociation of the antigen-binding site / antigen complex, which depend on the concentrations of the complex partners, the affinity of the interaction, and geometric parameters that affect the rates in both directions equally. Thus, the "association rate constant" (K on ) and "dissociation rate constant" (K off ) can be determined by calculating the concentration and the actual rates of association and dissociation. (See Malmqvist, Nature 361:186-187 (1993)). K off / K on The ratio of A to D allows the cancellation of all parameters not related to affinity and the dissociation constant K d (See Davies et al. (1990) Annual Rev Biochem 59:439-473.) The equilibrium binding constant (K d) is ≦10 μM, preferably ≦10 nM, more preferably ≦10 nM, and most preferably ≦100 pM to about 1 pM. In some embodiments, surface plasmon resonance (SPR) is used to measure the K of an antibody, typically using a biosensor system such as a Biacore® system. d In some embodiments, the K of an antibody is measured by a platform based on biolayer interferometry technology, such as the Octet system (Creative Biolabs, Shirley, NY). d Measure.
[0037] In some embodiments, the anti-VISTA antibodies or antigen-binding portions provided herein are monovalent or bivalent and comprise single or two chains. Functionally, the binding affinity of the antibodies or antigen-binding portions is greater than or equal to 10 -5 M~10 -12 For example, the binding affinity of an antibody or antigen-binding portion may be in the range of 10 -6 M~10 -12 M, 10 -7 M~10 -12 M, 10 -8 M~10 -12 M, 10 -9 M~10 -12 M, 10 -5 M~10 -11 M, 10 -6 M~10 -11 M, 10 -7 M~10 -11 M, 10 -8 M~10 -11 M, 10 -9 M~10 -11 M, 10 -10 M~10 -11 M, 10 -5 M~10 -10 M, 10 -6 M~10 -10 M, 10 -7 M~10 -10 M, 10 -8 M~10 -10 M, 10 -9 M~10 -10M, 10 -5 M~10 -9 M, 10 -6 M~10 -9 M, 10 -7 M~10 -9 M, 10 -8 M~10 -9 M, 10 -5 M~10 -8 M, 10 -6 M~10 -8 M, 10 -7 M~10 -8 M, 10 -5 M~10 -7 M, 10 -6 M~10 -7 M or 10 -5 M~10 -6 It's M.
[0038] In some embodiments, the monovalent affinity at pH 6.0 (K) of the anti-VISTA antibodies or antigen-binding portions provided herein as measured by SPR is d In some embodiments, the monovalent affinity (K) at pH 6.0 of an anti-VISTA antibody or antigen-binding portion provided herein as measured by SPR is less than 9 nM, less than 8 nM, less than 7 nM, less than 6 nM, less than 5 nM, less than 4 nM, less than 3 nM, less than 2 nM, less than 1 nM, less than 0.5 nM, or less than 0.25 nM. d ) is about 0.1 nM to about 0.5 nM, about 0.2 nM to about 0.4 nM, or about 0.2 nM to about 0.3 nM.
[0039] In some embodiments, the monovalent affinity (K) at physiological pH (pH 7.0-7.4) of the anti-VISTA antibodies or antigen-binding portions provided herein, as measured by SPR, is d ) is greater than 100 nM. In some embodiments, there is no detectable non-specific binding to VISTA at physiological pH (pH 7.0-7.4) by anti-VISTA antibodies or antigen-binding portions provided herein as measured by SPR.
[0040] In some embodiments, the monovalent affinity at pH 6.0 (K) of the anti-VISTA antibodies or antigen-binding portions provided herein as measured by SPR is d ) is about 0.2 nM to about 0.3 nM, and the monovalent affinity (K d ) is greater than 100 nM.
[0041] In some embodiments, the monovalent affinity at pH 6.0 (K d ) is the monovalent affinity (K d ) at least 100 times smaller, at least 200 times smaller, at least 300 times smaller, at least 400 times smaller, or at least 500 times smaller.
[0042] Provided herein are anti-VISTA antibodies or antigen-binding portions thereof, the antibodies or antigen-binding portions being selected from the group consisting of antibodies 55873, 67373, 67374, 67375, 67376, 67377, 67378, 67379, 67380, 67381, 67382, 55902, 67414, 67415, 67416, 67417, 67418, 67419, 67420, 67422, 67423, 67424, 55872, 55879, 55880, 55899, 55901, 55932 or 55934, or anti-VISTA antibodies. and cross-competes for binding to VISTA with an antibody comprising one or more of the amino acid sequences set forth in Tables 1-29 of the polypeptides 55873, 67373, 67374, 67375, 67376, 67377, 67378, 67379, 67380, 67381, 67382, 55902, 67414, 67415, 67416, 67417, 67418, 67419, 67420, 67422, 67423, 67424, 55872, 55879, 55880, 55899, 55901, 55932 or 55934 (see Tables 1-29).
[0043] The terms "cross-compete", "cross-compete", "cross-blocking", "cross-blocked" and "cross-blocking" are used interchangeably herein to refer to the ability of an antibody or antigen-binding portion thereof to directly or indirectly interfere with the binding of an anti-VISTA antibody of the present disclosure to a target VISTA (e.g., human VISTA) via allosteric modulation. The extent to which an antibody or portion thereof can interfere with the binding of another antibody or portion thereof to a target, and therefore whether it can be said to cross-block or cross-compete, can be determined using a competitive binding assay. One example of a binding competition assay is homogeneous time-resolved fluorescence (HTRF). In one particularly suitable quantitative cross-competition assay, FACS or Alphascreen-based techniques are used to measure the competition between a labeled (e.g., His-tagged, biotinylated or radiolabeled) antibody or portion thereof and another antibody or portion thereof for their binding to a target. Generally, a cross-competing antibody or portion thereof is one that binds to a target in a cross-competition assay such that, for example, during the assay, in the presence of a second antibody or portion thereof, the recorded displacement of an immunoglobulin single variable domain or polypeptide according to the invention is up to 100% (e.g., in a FACS-based competition assay) of the maximum theoretical displacement by a potentially cross-blocking antibody or fragment thereof present in a given amount (e.g., displacement by a cold (e.g., unlabeled) antibody or fragment thereof that needs to be cross-blocked). In some embodiments, a cross-competing antibody or portion thereof has a recorded displacement that is between 10% and 100%, or between 50% and 100%.
[0044] Provided herein is an anti-VISTA antibody, or antigen-binding portion thereof, that cross-competes for binding to VISTA with an antibody comprising a VH region and a VL region, and (a) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 54, an HCDR2 comprising SEQ ID NO: 55, and an HCDR3 comprising SEQ ID NO: 56, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 57, an LCDR2 comprising SEQ ID NO: 58, and an LCDR3 comprising SEQ ID NO: 59; or (b) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 60, an HCDR2 comprising SEQ ID NO: 61, and an HCDR3 comprising SEQ ID NO: 62. (c) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 62, HCDR2 comprising SEQ ID NO: 63, and HCDR3 comprising SEQ ID NO: 56, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 57, LCDR2 comprising SEQ ID NO: 58, and LCDR3 comprising SEQ ID NO: 59; or (d) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 64, HCDR2 comprising SEQ ID NO: 65. (e) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 69, an HCDR2 comprising SEQ ID NO: 70, and an HCDR3 comprising SEQ ID NO: 56, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 57, an LCDR2 comprising SEQ ID NO: 67, and an LCDR3 comprising SEQ ID NO: 68; or (f) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 60, an HCDR2 comprising SEQ ID NO: 60, and an HCDR3 comprising SEQ ID NO: 57. (g) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 73, an HCDR2 comprising SEQ ID NO: 65, and an HCDR3 comprising SEQ ID NO: 74, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 57, an LCDR2 comprising SEQ ID NO: 58, and an LCDR3 comprising SEQ ID NO: 71; or (h) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 64,(i) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 64, HCDR2 comprising SEQ ID NO: 65, and HCDR3 comprising SEQ ID NO: 77, the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 57, LCDR2 comprising SEQ ID NO: 78, and LCDR3 comprising SEQ ID NO: 68, or (j) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 60. (k) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 54, an HCDR2 comprising SEQ ID NO: 65, and an HCDR3 comprising SEQ ID NO: 79, the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 80, an LCDR2 comprising SEQ ID NO: 58, and an LCDR3 comprising SEQ ID NO: 68, or (l) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 81, an HCDR2 comprising SEQ ID NO: 55, and an HCDR3 comprising SEQ ID NO: 56, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 57, an LCDR2 comprising SEQ ID NO: 58, and an LCDR3 comprising SEQ ID NO: 68. (m) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 87, HCDR2 comprising SEQ ID NO: 88, and HCDR3 comprising SEQ ID NO: 83, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 84, LCDR2 comprising SEQ ID NO: 85, and LCDR3 comprising SEQ ID NO: 86; or (n) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 87, HCDR2 comprising SEQ ID NO: 88, and HCDR3 comprising SEQ ID NO: 83, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 84, LCDR2 comprising SEQ ID NO: 85, and LCDR3 comprising SEQ ID NO: 86. (o) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 91, HCDR2 comprising SEQ ID NO: 92 and HCDR3 comprising SEQ ID NO: 83, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 84, LCDR2 comprising SEQ ID NO: 85 and LCDR3 comprising SEQ ID NO: 86; or (p) the VH region amino acid sequence comprises(q) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 98, HCDR2 comprising SEQ ID NO: 99 and HCDR3 comprising SEQ ID NO: 100, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 96, LCDR2 comprising SEQ ID NO: 101 and LCDR3 comprising SEQ ID NO: 102; or (r) the VH (s) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 103, an HCDR2 comprising SEQ ID NO: 104, and an HCDR3 comprising SEQ ID NO: 105, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 96, an LCDR2 comprising SEQ ID NO: 106, and an LCDR3 comprising SEQ ID NO: 107, or (s) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 108, an HCDR2 comprising SEQ ID NO: 94, and an HCDR3 comprising SEQ ID NO: 105, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 109, an LCDR2 comprising SEQ ID NO: 85, and an LCDR3 comprising SEQ ID NO: 110. (t) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 111, HCDR2 comprising SEQ ID NO: 94, and HCDR3 comprising SEQ ID NO: 112, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 96, LCDR2 comprising SEQ ID NO: 85, and LCDR3 comprising SEQ ID NO: 113, or (u) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 87, HCDR2 comprising SEQ ID NO: 94, and HCDR3 comprising SEQ ID NO: 114, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 115, LCDR2 comprising SEQ ID NO: 85, (v) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 93, HCDR2 comprising SEQ ID NO: 90, and HCDR3 comprising SEQ ID NO: 117, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 118, LCDR2 comprising SEQ ID NO: 85, and LCDR3 comprising SEQ ID NO: 86, or (w) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 119, HCDR2 comprising SEQ ID NO: 120, and HCDR3 comprising SEQ ID NO: 121, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 57,or (x) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 123, an HCDR2 comprising SEQ ID NO: 124, and an HCDR3 comprising SEQ ID NO: 125, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 126, an LCDR2 comprising SEQ ID NO: 127, and an LCDR3 comprising SEQ ID NO: 128; or (y) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 123, an HCDR2 comprising SEQ ID NO: 124, and an HCDR3 comprising SEQ ID NO: 129, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 57, an LCDR2 comprising SEQ ID NO: 58, and an LCDR3 comprising SEQ ID NO: 130; or (z) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 131, an HCDR2 comprising SEQ ID NO: 132, and an HCDR3 comprising SEQ ID NO: 133, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 126, an LCDR2 comprising SEQ ID NO: 134, and an LCDR3 comprising SEQ ID NO: or (aa) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 131, an HCDR2 comprising SEQ ID NO: 132, and an HCDR3 comprising SEQ ID NO: 136, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 57, an LCDR2 comprising SEQ ID NO: 58, and an LCDR3 comprising SEQ ID NO: 137; or (bb) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 54, an HCDR2 comprising SEQ ID NO: 138, and an HCDR3 comprising SEQ ID NO: 139, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 57, an LCDR2 comprising SEQ ID NO: 58, and an LCDR3 comprising SEQ ID NO: 140; or (cc) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 81, an HCDR2 comprising SEQ ID NO: 82, and an HCDR3 comprising SEQ ID NO: 141, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 142, an LCDR2 comprising SEQ ID NO: 143, and an LCDR3 comprising SEQ ID NO: 144.
[0045] Provided herein are anti-VISTA antibodies, or antigen-binding portions thereof, that cross-compete for binding to VISTA with an antibody or antigen-binding portion comprising a set of CDRs disclosed herein; (a) specifically bind to human VISTA and cynomolgus VISTA; (b) have a Kd at pH 6 that is at least 500-fold lower than at physiological pH (pH 7.0-7.4); (c) inhibit PSGL-1 / VISTA interaction; (d) attenuate VISTA-induced checkpoint inhibition; (e) induce tumor rejection in greater than 40% of syngeneic mice when used as monotherapy; and (f) induce tumor rejection in greater than 90% of syngeneic mice when combined with an anti-PD-1 inhibitor.
[0046] The antibodies disclosed herein are anti-VISTA antagonist antibodies. As used herein, "antagonist" or "anti-VISTA antagonist antibody" (interchangeably referred to as "anti-VISTA antibody") refers to an antibody capable of binding to VISTA and inhibiting the biological activity of VISTA and / or downstream pathway(s) mediated by VISTA signaling. Anti-VISTA antagonist antibodies include antibodies capable of blocking, antagonizing, inhibiting, or reducing (including significantly) the biological activity of VISTA, such as receptor binding and / or induction of a cellular response to VISTA, including downstream pathways mediated by VISTA signaling. For purposes of this disclosure, the term "anti-VISTA antagonist antibody" is expressly understood to include all terms, names, and functional states and properties that substantially eliminate, reduce, or to a meaningful extent neutralize VISTA itself, and the biological activity of VISTA, including but not limited to its ability to negatively regulate T cells, or the consequences of the activity or biological activity.
[0047] Provided herein are anti-VISTA antibodies, or antigen-binding portions thereof, that inhibit the PSGL-1 / VISTA interaction. Provided herein are anti-VISTA antibodies, or antigen-binding portions thereof, that inhibit the VSIG-3 / VISTA interaction. Provided herein are anti-VISTA antibodies, or antigen-binding portions thereof, that inhibit the VSIG-8 / VISTA interaction. Provided herein are anti-VISTA antibodies, or antigen-binding portions thereof, that inhibit the syndecan-2 / VISTA interaction. Provided herein are anti-VISTA antibodies, or antigen-binding portions thereof, that inhibit the LRIG-1 / VISTA interaction.
[0048] Further provided herein are anti-VISTA antibodies or antigen-binding portions thereof comprising one or more amino acid sequences of antibodies 55873, 67373, 67374, 67375, 67376, 67377, 67378, 67379, 67380, 67381, 67382, 55902, 67414, 67415, 67416, 67417, 67418, 67419, 67420, 67422, 67423, 67424, 55872, 55879, 55880, 55899, 55901, 55932 or 55934. The combinations of VH region, VL region and CDR sequences which form these antibodies are set forth in Tables 1-29. In some embodiments, the VH region sequence and / or the VL region sequence comprises a signal sequence (also known as a signal peptide) at the amino terminus.
[0049] Provided herein are anti-VISTA antibodies, or antigen-binding portions thereof, comprising a heavy chain variable (VH) region and a light chain variable (VL) region, wherein (a) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO:54, HCDR2 comprising SEQ ID NO:55, and HCDR3 comprising SEQ ID NO:56, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO:57, LCDR2 comprising SEQ ID NO:58, and LCDR3 comprising SEQ ID NO:59, or (b) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO:60, HCDR2 comprising SEQ ID NO:61, and LCDR3 comprising SEQ ID NO:62. 2 and HCDR3 comprising SEQ ID NO:56, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO:57, LCDR2 comprising SEQ ID NO:58, and LCDR3 comprising SEQ ID NO:59; (c) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO:62, HCDR2 comprising SEQ ID NO:63, and HCDR3 comprising SEQ ID NO:56, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO:57, LCDR2 comprising SEQ ID NO:58, and LCDR3 comprising SEQ ID NO:59; or (d) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO:64, HCDR2 comprising SEQ ID NO:65. (e) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 69, HCDR2 comprising SEQ ID NO: 70 and HCDR3 comprising SEQ ID NO: 56, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 57, LCDR2 comprising SEQ ID NO: 67 and LCDR3 comprising SEQ ID NO: 71; or (f) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 60, HCDR2 comprising SEQ ID NO: 61 and LCDR3 comprising SEQ ID NO: 62. (g) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 73, an HCDR2 comprising SEQ ID NO: 65, and an HCDR3 comprising SEQ ID NO: 74, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 57, an LCDR2 comprising SEQ ID NO: 58, and an LCDR3 comprising SEQ ID NO: 71; or (h) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 64,(i) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 64, HCDR2 comprising SEQ ID NO: 65, and HCDR3 comprising SEQ ID NO: 77, the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 57, LCDR2 comprising SEQ ID NO: 78, and LCDR3 comprising SEQ ID NO: 68, or (j) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 60. (k) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 54, an HCDR2 comprising SEQ ID NO: 65, and an HCDR3 comprising SEQ ID NO: 79, the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 80, an LCDR2 comprising SEQ ID NO: 58, and an LCDR3 comprising SEQ ID NO: 68, or (l) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 81, an HCDR2 comprising SEQ ID NO: 55, and an HCDR3 comprising SEQ ID NO: 56, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 57, an LCDR2 comprising SEQ ID NO: 58, and an LCDR3 comprising SEQ ID NO: 68. (m) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 87, HCDR2 comprising SEQ ID NO: 88, and HCDR3 comprising SEQ ID NO: 83, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 84, LCDR2 comprising SEQ ID NO: 85, and LCDR3 comprising SEQ ID NO: 86; or (n) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 87, HCDR2 comprising SEQ ID NO: 88, and HCDR3 comprising SEQ ID NO: 83, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 84, LCDR2 comprising SEQ ID NO: 85, and LCDR3 comprising SEQ ID NO: 86. (o) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 91, HCDR2 comprising SEQ ID NO: 92 and HCDR3 comprising SEQ ID NO: 83, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 84, LCDR2 comprising SEQ ID NO: 85 and LCDR3 comprising SEQ ID NO: 86; or (p) the VH region amino acid sequence comprises(q) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 98, HCDR2 comprising SEQ ID NO: 99 and HCDR3 comprising SEQ ID NO: 100, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 96, LCDR2 comprising SEQ ID NO: 101 and LCDR3 comprising SEQ ID NO: 102; or (r) the VH (s) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 103, an HCDR2 comprising SEQ ID NO: 104, and an HCDR3 comprising SEQ ID NO: 105, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 96, an LCDR2 comprising SEQ ID NO: 106, and an LCDR3 comprising SEQ ID NO: 107, or (s) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 108, an HCDR2 comprising SEQ ID NO: 94, and an HCDR3 comprising SEQ ID NO: 105, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 109, an LCDR2 comprising SEQ ID NO: 85, and an LCDR3 comprising SEQ ID NO: 110. (t) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 111, HCDR2 comprising SEQ ID NO: 94, and HCDR3 comprising SEQ ID NO: 112, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 96, LCDR2 comprising SEQ ID NO: 85, and LCDR3 comprising SEQ ID NO: 113, or (u) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 87, HCDR2 comprising SEQ ID NO: 94, and HCDR3 comprising SEQ ID NO: 114, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 115, LCDR2 comprising SEQ ID NO: 85, (v) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 93, HCDR2 comprising SEQ ID NO: 90, and HCDR3 comprising SEQ ID NO: 117, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 118, LCDR2 comprising SEQ ID NO: 85, and LCDR3 comprising SEQ ID NO: 86, or (w) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 119, HCDR2 comprising SEQ ID NO: 120, and HCDR3 comprising SEQ ID NO: 121, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 57,or (x) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 123, an HCDR2 comprising SEQ ID NO: 124, and an HCDR3 comprising SEQ ID NO: 125, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 126, an LCDR2 comprising SEQ ID NO: 127, and an LCDR3 comprising SEQ ID NO: 128; or (y) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 123, an HCDR2 comprising SEQ ID NO: 124, and an HCDR3 comprising SEQ ID NO: 129, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 57, an LCDR2 comprising SEQ ID NO: 58, and an LCDR3 comprising SEQ ID NO: 130; or (z) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 131, an HCDR2 comprising SEQ ID NO: 132, and an HCDR3 comprising SEQ ID NO: 133, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 126, an LCDR2 comprising SEQ ID NO: 134, and an LCDR3 comprising SEQ ID NO: or (aa) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 131, an HCDR2 comprising SEQ ID NO: 132, and an HCDR3 comprising SEQ ID NO: 136, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 57, an LCDR2 comprising SEQ ID NO: 58, and an LCDR3 comprising SEQ ID NO: 137; or (bb) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 54, an HCDR2 comprising SEQ ID NO: 138, and an HCDR3 comprising SEQ ID NO: 139, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 57, an LCDR2 comprising SEQ ID NO: 58, and an LCDR3 comprising SEQ ID NO: 140; or (cc) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 81, an HCDR2 comprising SEQ ID NO: 82, and an HCDR3 comprising SEQ ID NO: 141, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 142, an LCDR2 comprising SEQ ID NO: 143, and an LCDR3 comprising SEQ ID NO: 144.
[0050] Provided herein are anti-VISTA antibodies, or antigen-binding portions thereof, comprising a VH region and a VL region, wherein (a) the VH region amino acid sequence comprises SEQ ID NO:1 and the VL region amino acid sequence comprises SEQ ID NO:2; (b) the VH region amino acid sequence comprises SEQ ID NO:3 and the VL region amino acid sequence comprises SEQ ID NO:2; (c) the VH region amino acid sequence comprises SEQ ID NO:4 and the VL region amino acid sequence comprises SEQ ID NO:2; (d) the VH region amino acid sequence comprises SEQ ID NO:5 and the VL region amino acid sequence comprises SEQ ID NO:6; or (e) the VH region amino acid sequence comprises SEQ ID NO:7 and the VL region amino acid sequence comprises SEQ ID NO:8. (f) the VH region amino acid sequence comprises SEQ ID NO: 9 and the VL region amino acid sequence comprises SEQ ID NO: 10; (g) the VH region amino acid sequence comprises SEQ ID NO: 11 and the VL region amino acid sequence comprises SEQ ID NO: 12; (h) the VH region amino acid sequence comprises SEQ ID NO: 13 and the VL region amino acid sequence comprises SEQ ID NO: 14; (i) the VH region amino acid sequence comprises SEQ ID NO: 15 and the VL region amino acid sequence comprises SEQ ID NO: 16; or (j) the VH region amino acid sequence comprises SEQ ID NO: 17 and the VL region amino acid sequence comprises SEQ ID NO: 18. (k) the VH region amino acid sequence comprises SEQ ID NO:19 and the VL region amino acid sequence comprises SEQ ID NO:20; (l) the VH region amino acid sequence comprises SEQ ID NO:21 and the VL region amino acid sequence comprises SEQ ID NO:22; (m) the VH region amino acid sequence comprises SEQ ID NO:23 and the VL region amino acid sequence comprises SEQ ID NO:22; (n) the VH region amino acid sequence comprises SEQ ID NO:24 and the VL region amino acid sequence comprises SEQ ID NO:22; (o) the VH region amino acid sequence comprises SEQ ID NO:25 and the VL region amino acid sequence comprises SEQ ID NO:22; (p) the VH (q) the VH region amino acid sequence comprises SEQ ID NO:28 and the VL region amino acid sequence comprises SEQ ID NO:29; (r) the VH region amino acid sequence comprises SEQ ID NO:30 and the VL region amino acid sequence comprises SEQ ID NO:31; (s) the VH region amino acid sequence comprises SEQ ID NO:32 and the VL region amino acid sequence comprises SEQ ID NO:33; (t) the VH region amino acid sequence comprises SEQ ID NO:34 and the VL region amino acid sequence comprises SEQ ID NO:35; or (u) the VH region amino acid sequence comprises SEQ ID NO:36;(v) the VH region amino acid sequence comprises SEQ ID NO:38 and the VL region amino acid sequence comprises SEQ ID NO:39; (w) the VH region amino acid sequence comprises SEQ ID NO:40 and the VL region amino acid sequence comprises SEQ ID NO:41; (x) the VH region amino acid sequence comprises SEQ ID NO:42 and the VL region amino acid sequence comprises SEQ ID NO:43; (y) the VH region amino acid sequence comprises SEQ ID NO:44 and the VL region amino acid sequence comprises SEQ ID NO:45; (z) the VH region amino acid sequence comprises SEQ ID NO:46 and the VL region amino acid sequence comprises SEQ ID NO:47; (aa) the VH region amino acid sequence comprises SEQ ID NO:48 and the VL region amino acid sequence comprises SEQ ID NO:49; (bb) the VH region amino acid sequence comprises SEQ ID NO:50 and the VL region amino acid sequence comprises SEQ ID NO:51; or (cc) the VH region amino acid sequence comprises SEQ ID NO:52 and the VL region amino acid sequence comprises SEQ ID NO:53.
[0051] Provided herein are anti-VISTA antibodies, or antigen-binding portions thereof, which comprise a VH region and a VL region, and wherein the VH region amino acid sequence comprises SEQ ID NO:1, 3, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 24, 25, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50 or 52, or an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:1, 3, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 24, 25, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50 or 52.
[0052] Provided herein are anti-VISTA antibodies, or antigen-binding portions thereof, which comprise a VH region and a VL region, wherein the VL region amino acid sequence comprises SEQ ID NO: 2, 6, 8, 10, 12, 14, 16, 18, 20, 22, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51 or 53, or an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 2, 6, 8, 10, 12, 14, 16, 18, 20, 22, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51 or 53.
[0053] Provided herein are anti-VISTA antibodies, or antigen-binding portions thereof, comprising a VH region and a VL region, wherein (a) the VH region amino acid sequence comprises SEQ ID NO:1, or an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:1, and the VL region amino acid sequence comprises SEQ ID NO:2, or an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:2; or (b) the VH region amino acid sequence comprises SEQ ID NO:3, or an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:3. or (c) a VH region amino acid sequence comprises an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:4 or an amino acid sequence of SEQ ID NO:4, and a VL region amino acid sequence comprises an amino acid sequence at least 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:4 or an amino acid sequence of SEQ ID NO:4, and a VL region amino acid sequence comprises an amino acid sequence at least 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:4 or an amino acid sequence of SEQ ID NO:4, or (d) the VH region amino acid sequence comprises an amino acid sequence set forth in SEQ ID NO:5 or an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:5 and the VL region amino acid sequence comprises an amino acid sequence set forth in SEQ ID NO:6 or an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:6; or (e) the VH region amino acid sequence comprises an amino acid sequence set forth in SEQ ID NO:7 or an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:7. (f) the VH region amino acid sequence comprises SEQ ID NO:9 or an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:9 and the VL region amino acid sequence comprises SEQ ID NO:10 or an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:10;(g) the VH region amino acid sequence comprises SEQ ID NO:11, or an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:11, and the VL region amino acid sequence comprises SEQ ID NO:12, or an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:12; or (h) the VH region amino acid sequence comprises SEQ ID NO:13, or an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:13, and the VL region (i) the VH region amino acid sequence comprises SEQ ID NO:15 or an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:15, and the VL region amino acid sequence comprises SEQ ID NO:16 or an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:16; or (j) the VH region amino acid sequence comprises SEQ ID NO:15 or an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:16. or (k) the VH region amino acid sequence comprises SEQ ID NO:19 or an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:19 and the VL .... (l) the VH region amino acid sequence comprises SEQ ID NO:21 or an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:21 and the VL region amino acid sequence comprises SEQ ID NO:22 or an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:22; or (m) the VH region amino acid sequence comprises SEQ ID NO:23,or (n) a VH region amino acid sequence comprises an amino acid sequence at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:23, and the VL region amino acid sequence comprises SEQ ID NO:22, or an amino acid sequence at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:22; or (n) a VH region amino acid sequence comprises an amino acid sequence at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:24, or an amino acid sequence at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:24, and the VL region amino acid sequence comprises SEQ ID NO:22, or an amino acid sequence at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:22. or (o) the VH region amino acid sequence comprises an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:25 or SEQ ID NO:25, and the VL region amino acid sequence comprises an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:22 or SEQ ID NO:22; or (p) the VH region amino acid sequence comprises an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:26 or SEQ ID NO:26. or (q) a VH region amino acid sequence comprises an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:28 or the amino acid sequence of SEQ ID NO:28 and a VL region amino acid sequence comprises an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:29 or the amino acid sequence of SEQ ID NO:29; , 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:30, or an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:30, and the VL region amino acid sequence comprises SEQ ID NO:31, or an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:31, or an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:31, or an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:32 ....or (t) a VH region amino acid sequence comprises an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:34 or the amino acid sequence of SEQ ID NO:34 and a VL region amino acid sequence comprises an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:35 or the amino acid sequence of SEQ ID NO:35. or (u) the VH region amino acid sequence comprises SEQ ID NO:36, or an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:36, and the VL region amino acid sequence comprises SEQ ID NO:37, or an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:37; or (v) the VH region amino acid sequence comprises SEQ ID NO:38, or an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:38. (w) the VH region amino acid sequence comprises SEQ ID NO:40 or an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:40 and the VL region amino acid sequence comprises SEQ ID NO:41 or an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:41; or (x) (y) the VH region amino acid sequence comprises SEQ ID NO:42 or an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:42, and the VL region amino acid sequence comprises SEQ ID NO:43 or an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:43; or (y) the VH region amino acid sequence comprises SEQ ID NO:44 or an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:44, and the VL region amino acid sequence comprisesor (z) the VH region amino acid sequence comprises SEQ ID NO:46, or an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:46, and the VL region amino acid sequence comprises SEQ ID NO:47, or an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:47; or (aa) the VH region amino acid sequence comprises SEQ ID NO:48, or an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:48, and the VL region amino acid sequence comprises SEQ ID NO:49, or an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:49. %, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:50, or the VL region amino acid sequence comprises SEQ ID NO:51, or the amino acid sequence of SEQ ID NO:51 is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:51, or the VL region amino acid sequence comprises SEQ ID NO:52, or the amino acid sequence of SEQ ID NO:52 is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:52, or the VL region amino acid sequence comprises SEQ ID NO:53, or the amino acid sequence of SEQ ID NO:53 is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:53.
[0054] Provided herein are anti-VISTA antibodies or antigen-binding portions thereof, which antibodies or antigen-binding portions thereof comprise a VH region and a VL region, and the sequences of the VH and VL regions are the same as or similar to those of antibodies 55873, 67373, 67374, 67375, 67376, 67377, 67378, 67379, 67380, 67381, 67382, 55902, 67414, 67415, 67416, 67417, 67418, 67419, 67420, 67421, 67422, 67423, 67424, 67425, 67426, 67427, 67428, 67429, 67430, 67431, 67432, 67433, 67434, 67435, 67436, 67437, 67438, 67439, 67440, 67441, 67442, 67443, 67444, 67445, 67446, 67447, 67448, 67449, 67450, 67451, 67452, 67453, 67454, 67455, 67456, 67457, 67458, 67459, 67460, 67461, 67462, 67463, 67464, 67465, 67466, 15, 67416, 67417, 67418, 67419, 67420, 67422, 67423, 67424, 55872, 55879, 55880, 55899, 55901, 55932 or 55934, and having one, two or three conservative amino acid substitutions in the VH region sequence, the VL region sequence, or both the VH region and the VL region sequences. In some embodiments, the conservative amino acid substitutions are made only in the FR sequences and not in the CDR sequences of the antibody or antigen binding portion.
[0055] In some embodiments, the anti-VISTA antibodies or antigen-binding portions provided herein are monoclonal. The term "monoclonal antibody" (Mab) refers to an antibody, or antigen-binding portion thereof, that is derived from a single copy or clone, such as any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced. Preferably, monoclonal antibodies exist in a homogenous or substantially homogenous population.
[0056] In some embodiments, the antibodies or antigen-binding portions provided herein may be isolated.
[0057] In some embodiments, the anti-VISTA antibodies or antigen-binding portions provided herein are human (e.g., fully human). A human antibody comprises human CDR sequences, human framework sequences, and human constant region sequences.
[0058] In some embodiments, the anti-VISTA antibodies or antigen-binding portions provided herein are chimeric. The term "chimeric" is intended to refer to an antibody molecule, or antigen-binding portion thereof, in which the variable domain sequences are derived from one species and at least one constant region sequence is derived from another species. Examples of chimeric antibodies and suitable techniques for making them are described in US 4,816,567, US 4,975,369, and US 4,816,397, each of which is incorporated herein by reference in its entirety.
[0059] The present disclosure encompasses modifications to the amino acid sequence of an antibody molecule or antigen-binding portion thereof as defined herein. For example, the present disclosure includes antibody molecules and corresponding antigen-binding portions thereof, including functionally equivalent variable regions and CDRs that do not significantly affect their properties, as well as variants with enhanced or decreased activity and / or affinity. For example, the amino acid sequence may be mutated to obtain an antibody with a desired binding affinity for VISTA. Insertions including amino- and / or carboxyl-terminal fusions, ranging in length from one residue to polypeptides containing 100 or more residues, as well as intrasequence insertions of single or multiple amino acid residues are contemplated. Examples of terminal insertions include antibody molecules with an N-terminal methionyl residue or fused to an epitope tag. Other antibody molecule variants with insertions include fusion to the N- or C-terminus of the antibody of an enzyme or a polypeptide that extends the antibody's blood circulation half-life.
[0060] In some embodiments, the anti-VISTA antibodies or antigen binding portions provided herein can include glycosylated and non-glycosylated polypeptides, as well as polypeptides that have other post-translational modifications, such as, for example, glycosylation with different sugars, acetylation, and phosphorylation. The antibodies or antigen binding portions can be mutated to alter such post-translational modifications, for example, by adding, removing, or substituting one or more amino acid residues to create or remove a glycosylation site.
[0061] In some embodiments, the anti-VISTA antibodies or antigen-binding portions provided herein may be modified, for example, by amino acid substitution, to remove potential proteolytic sites in the antibody or portion.
[0062] In some embodiments, the anti-VISTA antibody, or antigen-binding portion thereof, comprises an immunoglobulin constant region. In some embodiments, the immunoglobulin constant region is IgG, IgE, IgM, IgD, IgA, or IgY. In some embodiments, the immunoglobulin constant region is IgG1, IgG2, IgG3, IgG4, IgA1, or IgA2. In some embodiments, the immunoglobulin constant region comprises one or more mutations to enhance FcγR binding, antibody-dependent cell-mediated cytotoxicity, and / or complement-dependent cytotoxicity. In some embodiments, the immunoglobulin constant region is immunologically inert. In some embodiments, the immunoglobulin constant region comprises one or more mutations to reduce or prevent FcγR binding, antibody-dependent cell-mediated cytotoxicity, and / or complement-dependent cytotoxicity. In some embodiments, the immunoglobulin constant region is a wild-type human IgG1 constant region, a wild-type human IgG2 constant region, a wild-type human IgG4 constant region, a human IgG1 constant region comprising the amino acid substitutions L234A, L235A and G237A, a human IgG1 constant region comprising the amino acid substitutions L234A, L235A, G237A and P331S, or a human IgG4 constant region comprising the amino acid substitution S228P, numbering according to the EU index as in Kabat. In some embodiments, amino acid residue positions within a constant region of an immunoglobulin molecule are numbered according to the EU index as in Kabat (Ward et al., 1995 Therap. Immunol. 2:77-94).
[0063] In some embodiments, an anti-VISTA antibody, or antigen binding portion thereof, may comprise an immunoglobulin light chain constant region that is a kappa light chain constant region or a lambda light chain constant region.
[0064] In some embodiments, the anti-VISTA antibody may comprise an immunoglobulin constant region comprising any one of the amino acid sequences in Table 30. The Fc region sequences in Table 30 begin with the CH1 domain. In some embodiments, the anti-VISTA antibody may comprise an immunoglobulin constant region comprising the amino acid sequence of a human IgG4 or human IgG1 Fc region. In some embodiments, the anti-VISTA antibody may comprise an immunoglobulin constant region comprising the amino acid sequence of a human IgG4, human IgG4(S228P), human IgG2, human IgG1, or human IgG1 effector-deficient Fc region. For example, a human IgG4(S228P) Fc region comprises a substitution of S228P compared to a wild-type human IgG4 Fc region. For example, a human IgG1 effector-deficient Fc region comprises substitutions of L234A, L235A, and G237A compared to a wild-type human IgG1 Fc region. In some embodiments, the anti-VISTA antibody may comprise an immunoglobulin constant region comprising any one of SEQ ID NOs: 145-149. In some embodiments, an anti-VISTA antibody may comprise the six CDR amino acid sequences of any one of the clones in Tables 1-29, and any one of the Fc region amino acid sequences in Table 30. In some embodiments, an anti-VISTA antibody may comprise an immunoglobulin heavy chain constant region comprising any one of the Fc region amino acid sequences in Table 30, and an immunoglobulin light chain constant region that is a kappa light chain constant region or a lambda light chain constant region.
[0065] Further provided herein is an immunoconjugate comprising an anti-VISTA antibody, or an antigen-binding portion thereof, linked to a therapeutic agent, in some embodiments the therapeutic agent is a cytotoxin, a radioisotope, a chemotherapeutic agent, an immunomodulatory agent, a cytostatic enzyme, a cytolytic enzyme, a therapeutic peptide, a therapeutic nucleic acid, an angiogenesis inhibitor, an anti-proliferative agent, or a pro-apoptotic agent.
[0066] Examples of suitable therapeutic agents include, but are not limited to, immunomodulators, cytotoxins, radioisotopes, chemotherapeutic agents, angiogenesis inhibitors, antiproliferative agents, apoptosis promoters, and cytostatic and cytolytic enzymes (e.g., RNAses).Additional therapeutic agents include therapeutic nucleic acids, such as genes that code for immunomodulators, angiogenesis inhibitors, growth inhibitors, or apoptosis promoters.These drug descriptive names are not mutually exclusive, and thus therapeutic agents may be described using one or more of the above terms.
[0067] Examples of suitable therapeutic agents for use in immunoconjugates include, but are not limited to, JAK kinase inhibitors, taxanes, maytansines, CC-1065 and duocarmycins, calicheamicins and other enediynes, and auristatins. Other examples include antifolates, vinca alkaloids, and anthracyclines. Plant toxins, other bioactive proteins, enzymes (i.e., ADEPT), radioisotopes, photosensitizers may also be used in immunoconjugates. In addition, conjugates can be made using secondary carriers, such as liposomes or polymers, as cytotoxic agents. Suitable cytotoxins include agents that inhibit or block the function of cells and / or cause the destruction of cells. Representative cytotoxins include antibiotics, inhibitors of tubulin polymerization, alkylating agents that bind to and destroy DNA, and agents that disrupt protein synthesis or the function of essential cellular proteins such as protein kinases, phosphatases, topoisomerases, enzymes, and cyclins.
[0068] Representative cytotoxins include doxorubicin, daunorubicin, idarubicin, aclarubicin, zorubicin, mitoxantrone, epirubicin, carubicin, nogalamycin, menogaril, pitarubicin, valrubicin, cytarabine, gemcitabine, trifluridine, ancitabine, enocitabine, azacytidine, doxifluridine, pentostatin, broxuhdine, capecitabine, cladhbine, decitabine, floxuhdine, fludarabine, gougerotin, puromycin, tegafur, thiazofuhn, adamycin, cis- These include, but are not limited to, platins, carboplatin, cyclophosphamide, dacarbazine, vinblastine, vincristine, mitoxantrone, bleomycin, mechlorethamine, prednisone, procarbazine, methotrexate, flurouracil, etoposide, taxol, taxol analogs, platins such as cisplatin and carboplatin, mitomycin, thiotepa, taxanes, vincristine, daunorubicin, epirubicin, actinomycin, authramycin, azaserine, bleomycin, tamoxifen, idarubicin, dolastatins / auristatins, hemiasterin, esperamicin, and maytansinoids.
[0069] Pharmaceutical Compositions The anti-VISTA antibodies and antigen-binding portions (also referred to herein as "active compounds") provided herein can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically include the anti-VISTA antibody or antigen-binding portion (or an immunoconjugate comprising such an antibody or portion) and a pharma- ceutically acceptable carrier, diluent or excipient. Such materials should be non-toxic and should not interfere with the effectiveness of the anti-VISTA antibody or antigen-binding fragment thereof. The precise nature of the carrier or other material will depend on the route of administration, as discussed below, which may be by injection, bolus, infusion, or any other suitable route.
[0070] As used herein, the term "pharmaceutically acceptable" refers to molecular entities and compositions that do not generally produce allergic reactions or other serious adverse reactions when administered using routes well known in the art. Molecular entities and compositions that are approved by a regulatory agency of the U.S. Federal or state government for use in animals, particularly humans, or that are listed in the U.S. Pharmacopeia or other generally recognized pharmacopoeias are considered to be "pharmaceutically acceptable." As used herein, the term "pharmaceutically acceptable carrier" is intended to include any solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonicity agents, and absorption delaying agents that are compatible with pharmaceutical administration. Suitable carriers are described in the latest edition of Remington's Pharmaceutical Sciences, a standard text in the art (herein incorporated by reference). Some examples of such carriers or diluents include, but are not limited to, water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin. Non-aqueous vehicles such as liposomes and fixed oils may also be used. The use of such media and agents for pharma- ceutical active substances is well known in the art. The use of any conventional media or agent in the compositions is contemplated, provided that it is not incompatible with the active compound. Supplementary active compounds can also be incorporated into the compositions. A pharma- ceutical acceptable carrier, diluent or excipient is a compound or combination of compounds that does not induce secondary reactions and can, for example, facilitate administration of the anti-VISTA antibody or antigen-binding portion thereof, increase its longevity and / or its availability in the body, or increase its solubility in solution.
[0071] The pharmaceutical compositions disclosed herein may be formulated to suit its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (i.e., topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application may contain the following components: a sterile diluent, such as water for injection, saline, fixed oils, polyethylene glycols, glycerin, propylene glycol, or other synthetic solvents; antibacterial agents, such as benzyl alcohol or methylparaben; antioxidants, such as ascorbic acid or sodium bisulfate; chelating agents, such as ethylenediaminetetraacetic acid (EDTA); buffers, such as acetates, citrates, or phosphates, and agents for adjusting isotonicity, such as sodium chloride or dextrose. The pH may be adjusted using acids or bases, such as hydrochloric acid or sodium hydroxide. Parenteral preparations may be enclosed in ampoules, disposable syringes, or multiple dose vials made of glass or plastic.
[0072] Pharmaceutical compositions suitable for injection include sterile aqueous solutions (where water soluble) or dispersions, and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL® (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be, for example, a solvent or dispersion medium containing water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. Prevention of microbial action can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, etc. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, aluminum monostearate and gelatin.
[0073] Sterile injection can be prepared by mixing the active compound in the required amount in a suitable solvent with one or a combination of the above-listed components as required, and then sterilizing by filtration.Generally, dispersion is prepared by combining the active compound with a sterile vehicle that contains a basic dispersion medium and other necessary components from the above-listed components.For the preparation of sterile powder for sterile injection, the preparation method is vacuum drying and freeze-drying, and the powder is obtained from the solution of the active ingredient to which any desired additional components are added, which is previously sterilized by filtration.
[0074] Oral compositions generally include an inert diluent or an edible carrier. They can be sealed in gelatin capsules or compressed into tablets. For therapeutic oral administration, active compounds can be combined with excipients and used in the form of tablets, lozenges, or capsules. Oral compositions can also be prepared using liquid carriers for use as mouthwash, and the compound in such liquid carriers is applied orally and swished in the mouth and expectorated or swallowed. Pharmaceutically compatible binding agents and / or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like may contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primojel®, or corn starch; a lubricant such as magnesium stearate; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
[0075] For administration by inhalation, the compounds can be delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
[0076] Systemic administration can also be via transmucosal or transdermal routes. For transmucosal or transdermal administration, a penetrant suitable for the barrier to be permeated is used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, lavage fluids, bile salts, and fusidic acid derivatives. Transmucosal administration can be achieved through the use of nasal sprays or suppositories. For transdermal administration, the active compound is formulated into ointments, salves, gels, or creams generally known in the art.
[0077] The pharmaceutical agents can also be prepared in the form of suppositories (eg, with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.
[0078] In some embodiments, the active compound is prepared with a carrier that protects the compound from rapid excretion from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.Biodegradable, biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid can be used.The method of preparing such formulations will be clear to those skilled in the art.Materials can also be commercially obtained.Liposomal suspensions can also be used as pharmaceutically acceptable carriers.
[0079] For the sake of ease of administration and uniformity of dosage, it is particularly convenient to formulate oral or parenteral compositions in dosage unit form.Dosage unit form as used herein refers to a physically discrete unit suitable as a unitary dose for the subject to be treated, each unit containing a predetermined amount of active compound calculated to produce a desired therapeutic effect in association with the required pharmaceutical carrier.The specification of the dosage unit form of the present invention is determined and directly depends on the inherent characteristics of the active compound and the specific therapeutic effect to be achieved, as well as the inherent constraints of the formulation technique of such active compound for treating individuals.
[0080] In some embodiments, the anti-VISTA antibody or antigen-binding portion thereof may be provided in lyophilized form for reconstitution prior to administration. For example, lyophilized antibody molecules may be reconstituted in sterile water and mixed with saline prior to administration to an individual.
[0081] The pharmaceutical compositions provided herein can be included in a container, pack, or dispenser together with instructions for administration.
[0082] Nucleic acid molecules, vectors, host cells and methods for producing antibodies Provided herein are nucleic acid molecules (e.g., isolated nucleic acid molecules) that encode the amino acid sequence of an anti-VISTA antibody or anti-VISTA antigen binding portion described herein (or the amino acid sequence of (i) the VH region, (ii) the VL region, or (iii) both the VH and VL regions of the antibody or antigen binding portion). Further provided herein are nucleic acid molecules (e.g., isolated nucleic acid molecules) that encode (i) the heavy chain, (ii) the light chain, or (iii) both the heavy and light chains of an anti-VISTA antibody or anti-VISTA antigen binding portion described herein. In some embodiments, the nucleic acid molecule encoding the VH region, VL region, heavy chain, or light chain comprises a signal sequence. In some embodiments, the nucleic acid molecule encoding the VH region, VL region, heavy chain, or light chain does not comprise a signal sequence.
[0083] In some embodiments, the nucleic acid molecule encodes amino acid sequences of the VH region and the VL region of an anti-VISTA antibody, or antigen-binding portion thereof, wherein (a) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO:54, an HCDR2 comprising SEQ ID NO:55, and an HCDR3 comprising SEQ ID NO:56, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO:57, an LCDR2 comprising SEQ ID NO:58, and an LCDR3 comprising SEQ ID NO:59, or (b) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO:60, an HCDR2 comprising SEQ ID NO:61, and an HCDR3 comprising SEQ ID NO:56. (c) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 62, HCDR2 comprising SEQ ID NO: 63, and HCDR3 comprising SEQ ID NO: 56, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 57, LCDR2 comprising SEQ ID NO: 58, and LCDR3 comprising SEQ ID NO: 59; or (d) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 64, HCDR2 comprising SEQ ID NO: 65, and HCDR3 comprising SEQ ID NO: 56, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 57, LCDR2 comprising SEQ ID NO: 58, and LCDR3 comprising SEQ ID NO: 59; (e) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 69, an HCDR2 comprising SEQ ID NO: 70, and an HCDR3 comprising SEQ ID NO: 56, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 57, an LCDR2 comprising SEQ ID NO: 67, and an LCDR3 comprising SEQ ID NO: 71; or (f) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 60, and an LCDR3 comprising SEQ ID NO: 61. (g) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 73, an HCDR2 comprising SEQ ID NO: 65, and an HCDR3 comprising SEQ ID NO: 74, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 57, an LCDR2 comprising SEQ ID NO: 58, and an LCDR3 comprising SEQ ID NO: 71; or (h) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 64,(i) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 64, HCDR2 comprising SEQ ID NO: 65, and HCDR3 comprising SEQ ID NO: 77, the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 57, LCDR2 comprising SEQ ID NO: 78, and LCDR3 comprising SEQ ID NO: 68, or (j) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 60. (k) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 54, an HCDR2 comprising SEQ ID NO: 65, and an HCDR3 comprising SEQ ID NO: 79, the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 80, an LCDR2 comprising SEQ ID NO: 58, and an LCDR3 comprising SEQ ID NO: 68, or (l) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 81, an HCDR2 comprising SEQ ID NO: 55, and an HCDR3 comprising SEQ ID NO: 56, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 57, an LCDR2 comprising SEQ ID NO: 58, and an LCDR3 comprising SEQ ID NO: 68. (m) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 87, HCDR2 comprising SEQ ID NO: 88, and HCDR3 comprising SEQ ID NO: 83, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 84, LCDR2 comprising SEQ ID NO: 85, and LCDR3 comprising SEQ ID NO: 86; or (n) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 87, HCDR2 comprising SEQ ID NO: 88, and HCDR3 comprising SEQ ID NO: 83, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 84, LCDR2 comprising SEQ ID NO: 85, and LCDR3 comprising SEQ ID NO: 86. (o) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 91, HCDR2 comprising SEQ ID NO: 92 and HCDR3 comprising SEQ ID NO: 83, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 84, LCDR2 comprising SEQ ID NO: 85 and LCDR3 comprising SEQ ID NO: 86; or (p) the VH region amino acid sequence comprises(q) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 98, HCDR2 comprising SEQ ID NO: 99 and HCDR3 comprising SEQ ID NO: 100, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 96, LCDR2 comprising SEQ ID NO: 101 and LCDR3 comprising SEQ ID NO: 102; or (r) the VH (s) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 103, an HCDR2 comprising SEQ ID NO: 104, and an HCDR3 comprising SEQ ID NO: 105, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 96, an LCDR2 comprising SEQ ID NO: 106, and an LCDR3 comprising SEQ ID NO: 107, or (s) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 108, an HCDR2 comprising SEQ ID NO: 94, and an HCDR3 comprising SEQ ID NO: 105, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 109, an LCDR2 comprising SEQ ID NO: 85, and an LCDR3 comprising SEQ ID NO: 110. (t) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 111, HCDR2 comprising SEQ ID NO: 94, and HCDR3 comprising SEQ ID NO: 112, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 96, LCDR2 comprising SEQ ID NO: 85, and LCDR3 comprising SEQ ID NO: 113, or (u) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 87, HCDR2 comprising SEQ ID NO: 94, and HCDR3 comprising SEQ ID NO: 114, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 115, LCDR2 comprising SEQ ID NO: 85, (v) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 93, HCDR2 comprising SEQ ID NO: 90, and HCDR3 comprising SEQ ID NO: 117, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 118, LCDR2 comprising SEQ ID NO: 85, and LCDR3 comprising SEQ ID NO: 86, or (w) the VH region amino acid sequence comprises HCDR1 comprising SEQ ID NO: 119, HCDR2 comprising SEQ ID NO: 120, and HCDR3 comprising SEQ ID NO: 121, and the VL region amino acid sequence comprises LCDR1 comprising SEQ ID NO: 57,or (x) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 123, an HCDR2 comprising SEQ ID NO: 124, and an HCDR3 comprising SEQ ID NO: 125, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 126, an LCDR2 comprising SEQ ID NO: 127, and an LCDR3 comprising SEQ ID NO: 128; or (y) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 123, an HCDR2 comprising SEQ ID NO: 124, and an HCDR3 comprising SEQ ID NO: 129, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 57, an LCDR2 comprising SEQ ID NO: 58, and an LCDR3 comprising SEQ ID NO: 130; or (z) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 131, an HCDR2 comprising SEQ ID NO: 132, and an HCDR3 comprising SEQ ID NO: 133, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 126, an LCDR2 comprising SEQ ID NO: 134, and an LCDR3 comprising SEQ ID NO: or (aa) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 131, an HCDR2 comprising SEQ ID NO: 132, and an HCDR3 comprising SEQ ID NO: 136, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 57, an LCDR2 comprising SEQ ID NO: 58, and an LCDR3 comprising SEQ ID NO: 137; or (bb) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 54, an HCDR2 comprising SEQ ID NO: 138, and an HCDR3 comprising SEQ ID NO: 139, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 57, an LCDR2 comprising SEQ ID NO: 58, and an LCDR3 comprising SEQ ID NO: 140; or (cc) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 81, an HCDR2 comprising SEQ ID NO: 82, and an HCDR3 comprising SEQ ID NO: 141, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 142, an LCDR2 comprising SEQ ID NO: 143, and an LCDR3 comprising SEQ ID NO: 144.
[0084] In some embodiments, the nucleic acid molecule encodes the amino acid sequence of the VH region and the VL region of an anti-VISTA antibody, or antigen-binding portion thereof, and (a) the VH region amino acid sequence comprises SEQ ID NO:1 and the VL region amino acid sequence comprises SEQ ID NO:2; (b) the VH region amino acid sequence comprises SEQ ID NO:3 and the VL region amino acid sequence comprises SEQ ID NO:2; (c) the VH region amino acid sequence comprises SEQ ID NO:4 and the VL region amino acid sequence comprises SEQ ID NO:2; (d) the VH region amino acid sequence comprises SEQ ID NO:5 and the VL region amino acid sequence comprises SEQ ID NO:6; or (e) the VH region amino acid sequence comprises SEQ ID NO:7 and the VL region amino acid sequence comprises SEQ ID NO:8. (f) the VH region amino acid sequence comprises SEQ ID NO:9 and the VL region amino acid sequence comprises SEQ ID NO:10; (g) the VH region amino acid sequence comprises SEQ ID NO:11 and the VL region amino acid sequence comprises SEQ ID NO:12; (h) the VH region amino acid sequence comprises SEQ ID NO:13 and the VL region amino acid sequence comprises SEQ ID NO:14; (i) the VH region amino acid sequence comprises SEQ ID NO:15 and the VL region amino acid sequence comprises SEQ ID NO:16; or (j) the VH region amino acid sequence comprises SEQ ID NO:17 and the VL region amino acid sequence comprises SEQ ID NO:18. (k) the VH region amino acid sequence comprises SEQ ID NO:19 and the VL region amino acid sequence comprises SEQ ID NO:20; (l) the VH region amino acid sequence comprises SEQ ID NO:21 and the VL region amino acid sequence comprises SEQ ID NO:22; (m) the VH region amino acid sequence comprises SEQ ID NO:23 and the VL region amino acid sequence comprises SEQ ID NO:22; (n) the VH region amino acid sequence comprises SEQ ID NO:24 and the VL region amino acid sequence comprises SEQ ID NO:22; (o) the VH region amino acid sequence comprises SEQ ID NO:25 and the VL region amino acid sequence comprises SEQ ID NO:22; (p) the VH (q) the VH region amino acid sequence comprises SEQ ID NO:28 and the VL region amino acid sequence comprises SEQ ID NO:29; (r) the VH region amino acid sequence comprises SEQ ID NO:30 and the VL region amino acid sequence comprises SEQ ID NO:31; (s) the VH region amino acid sequence comprises SEQ ID NO:32 and the VL region amino acid sequence comprises SEQ ID NO:33; (t) the VH region amino acid sequence comprises SEQ ID NO:34 and the VL region amino acid sequence comprises SEQ ID NO:35; or (u) the VH region amino acid sequence comprises SEQ ID NO:36;(v) the VH region amino acid sequence comprises SEQ ID NO:38 and the VL region amino acid sequence comprises SEQ ID NO:39; (w) the VH region amino acid sequence comprises SEQ ID NO:40 and the VL region amino acid sequence comprises SEQ ID NO:41; (x) the VH region amino acid sequence comprises SEQ ID NO:42 and the VL region amino acid sequence comprises SEQ ID NO:43; (y) the VH region amino acid sequence comprises SEQ ID NO:44 and the VL region amino acid sequence comprises SEQ ID NO:45; (z) the VH region amino acid sequence comprises SEQ ID NO:46 and the VL region amino acid sequence comprises SEQ ID NO:47; (aa) the VH region amino acid sequence comprises SEQ ID NO:48 and the VL region amino acid sequence comprises SEQ ID NO:49; (bb) the VH region amino acid sequence comprises SEQ ID NO:50 and the VL region amino acid sequence comprises SEQ ID NO:51; or (cc) the VH region amino acid sequence comprises SEQ ID NO:52 and the VL region amino acid sequence comprises SEQ ID NO:53.
[0085] Also provided herein is an expression vector comprising the nucleic acid molecule described herein. In certain vectors, the nucleic acid molecule is operably linked to one or more control sequences suitable for the expression of the nucleic acid segment in a host cell. In some cases, the expression vector comprises a sequence that mediates replication and comprises one or more selection markers. As used herein, "vector" refers to a construct that can deliver, preferably express, one or more gene(s) or sequence(s) of interest to a host cell. Examples of vectors include, but are not limited to, viral vectors, naked DNA or RNA expression vectors, plasmid vectors, cosmid vectors or phage vectors, DNA or RNA expression vectors associated with cationic condensing agents, DNA or RNA expression vectors encapsulated in liposomes, and certain eukaryotic cells, such as producer cells.
[0086] Provided herein is a recombinant host cell comprising an expression vector or nucleic acid molecule disclosed herein. A "host cell" includes an individual cell, cell line, or cell culture that can be or has been the recipient of a vector(s) for incorporation of a polynucleotide insert. A host cell includes the progeny of a single host cell. The progeny may not necessarily be completely identical (in morphology or genomic DNA complement) to the original parent cell due to natural, accidental, or deliberate mutation. An expression vector can be transfected into a host cell by standard techniques. Non-limiting examples include electroporation, calcium phosphate precipitation, DEAE-dextran transfection, and the like. In some embodiments, a recombinant host cell comprises a single vector or a single nucleic acid molecule encoding both the VH and VL regions of an anti-VISTA antibody or antigen-binding portion thereof. In some embodiments, the recombinant host cell comprises (i) a first vector or a first nucleic acid molecule encoding the VH region of an anti-VISTA antibody or antigen-binding portion thereof, and (ii) a second vector or a second nucleic acid molecule encoding the VL region of an anti-VISTA antibody or antigen-binding portion thereof.
[0087] The antibody molecules of the present invention, or antigen-binding portions thereof, can be produced using techniques well known in the art, such as recombinant techniques, phage display techniques, synthetic techniques, computational techniques or a combination of such techniques or other techniques readily known in the art.
[0088] Further provided herein are methods for producing anti-VISTA antibodies or antigen-binding portions thereof, including culturing a recombinant host cell comprising an expression vector described herein under conditions in which the nucleic acid segment is expressed, thereby producing the anti-VISTA antibody or antigen-binding portion. The antibody or antigen-binding portion may then be isolated from the host cell or culture. Anti-VISTA antibodies and antigen-binding portions thereof may be produced by any of a wide variety of methods known to those of skill in the art. In certain embodiments, anti-VISTA antibodies and antigen-binding portions thereof may be produced recombinantly. For example, a nucleic acid sequence encoding one or more of SEQ ID NOs: 1-144, or a portion thereof, may be introduced into a bacterial cell (e.g., E. coli, B. subtilis) or eukaryotic cell (e.g., yeast such as S. cerevisiae, or mammalian cell, e.g., CHO cell lines, various Cos cell lines, HeLa cells, HEK293 cells, various myeloma cell lines, or transformed B cells or hybridomas), or may be introduced into an in vitro translation system and the translated polypeptide isolated. In some embodiments, the antibody light and heavy chain proteins are produced intracellularly with a signal sequence that is removed upon production of the mature anti-VISTA antibody, or antigen-binding portion thereof.
[0089] One of ordinary skill in the art will be able to determine, without undue experimentation, whether an antibody or antigen-binding portion comprising a given polypeptide sequence binds to a VISTA protein using standard methods, such as Western blot, ELISA, etc.
[0090] Use of antibodies Provided herein are methods and uses of the anti-VISTA antibodies, anti-VISTA antigen-binding portions, immunoconjugates and pharmaceutical compositions described herein for providing a therapeutic benefit to a subject with cancer.
[0091] The anti-VISTA antibodies or antigen-binding portions thereof described herein may be used in methods of treatment of the human or animal body, e.g., prophylactic or preventative treatment (e.g., treatment prior to the onset of a condition in a subject, to reduce the risk that the subject will develop a condition; delay its onset; or reduce its severity after onset). Methods of treatment may include administering an anti-VISTA antibody or antigen-binding portion to a subject in need thereof.
[0092] In some embodiments, the anti-VISTA antibodies, or antigen binding portions thereof, described herein do not induce CRS when administered to a subject. In some embodiments, the anti-VISTA antibodies, or antigen binding portions thereof, described herein minimally induce CRS when administered to a subject. In some embodiments, the anti-VISTA antibodies, or antigen binding portions thereof, described herein minimally induce expression of any combination of IL-6, IL-10, CCL-2, CCL-5, CXCL-8, CXCL-10, IFN-γ, TNF-α, and IL-1RA when administered to a subject.
[0093] Provided herein are methods for inducing an immune response in a subject, the methods comprising administering to the subject a therapeutically effective amount of an anti-VISTA antibody or antigen-binding portion thereof, immunoconjugate or pharmaceutical composition disclosed herein. In some embodiments, the immune response is an immune response against cancer cells. In some embodiments, the immune response is antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity or antibody-dependent cellular phagocytosis. In some embodiments, the immune response is an antibody response. In some embodiments, the immune response is a cytotoxic response.
[0094] Provided herein are methods for treating or preventing cancer in a subject, comprising administering to the subject a therapeutically effective amount of an anti-VISTA antibody or antigen-binding portion thereof, immunoconjugate or pharmaceutical composition disclosed herein. In some embodiments, the cancer is a hematological malignancy. In some embodiments, the cancer is a myeloid malignancy. In some embodiments, the cancer is acute myeloid leukemia (AML). In some embodiments, the cancer is an epithelial cancer. In some embodiments, the cancer is a solid tumor. In some embodiments, the cancer is squamous cell carcinoma of the head and neck, melanoma, non-small cell lung cancer or colon cancer.
[0095] In some embodiments, the subject overexpresses VISTA. In some embodiments, the subject overexpresses VISTA in blood cells. In some embodiments, the subject overexpresses VISTA in immune cells. In some embodiments, the immune cells are tumor infiltrating immune cells. In some embodiments, the immune cells are bone marrow cells or monocytes.
[0096] In some embodiments, a subject may be treated with an anti-VISTA antibody or anti-VISTA antigen binding portion, immunoconjugate or pharmaceutical composition described herein and an additional therapeutic agent or therapy used to treat a VISTA-mediated disease or disorder, or a symptom or complication of a VISTA-mediated disease or disorder. The anti-VISTA antibody or anti-VISTA antigen binding portion and the additional therapeutic agent or therapy may be administered simultaneously or sequentially. In some embodiments, the additional therapeutic agent is an inhibitor of PD-1 or PD-L1.
[0097] In some embodiments, the subject is non-responsive or has developed resistance to cancer treatment with a PD-1 or PD-L1 inhibitor. In some embodiments, the methods provided herein further comprise administering a PD-1 or PD-L1 inhibitor to the subject. In some embodiments, administration of an anti-VISTA antibody, anti-VISTA antigen binding portion, immunoconjugate or pharmaceutical composition provided herein with a PD-1 or PD-L1 inhibitor results in a synergistic anti-cancer effect.
[0098] In some embodiments, the PD-1 or PD-L1 inhibitor is an antibody or antigen-binding portion thereof that inhibits the interaction between the human PD-1 receptor and its ligand, human PD-L1. Antibodies known in the art that bind to PD-1 and inhibit the interaction between PD-1 and its ligand, PD-L1, and stimulate an anti-tumor immune response are suitable for use in the methods disclosed herein. In some embodiments, the antibody or antigen-binding portion thereof specifically binds to or targets PD-1. For example, antibodies that target PD-1 include, for example, nivolumab (BMS-936558, Bristol-Myers Squibb), pembrolizumab (lambrolizumab, MK03475, Merck), dostarlimab, tislelizumab, and cemiplimab. Other suitable antibodies for use in the methods disclosed herein are the anti-PD-1 antibodies disclosed in US 8,008,449, which is incorporated herein by reference in its entirety. In certain embodiments, the antibody or antigen-binding portion thereof specifically binds to or targets PD-L1 and inhibits its interaction with PD-1. Antibodies known in the art that bind to PD-L1 and inhibit the interaction between PD-1 and PD-L1 and stimulate anti-tumor immune responses are suitable for use in the methods disclosed herein. For example, antibodies that target PD-L1 include BMS-936559 (also known as MDX 1105, Bristol-Myers Squibb), atezolizumab (Genentech), durvalumab (AstraZeneca), and avelumab (MSB0010718C). Other suitable antibodies that target PD-L1 are disclosed in US 7,943,743, which is incorporated herein by reference in its entirety. Any antibody that specifically binds to PD-1 or PD-L1, inhibits PD-1 / PD-L1 interaction, and stimulates an anti-tumor immune response is suitable for use in the methods disclosed herein.
[0099] As used herein, the term "effective amount" or "therapeutically effective amount" refers to an amount of a pharmaceutical agent, e.g., an anti-VISTA antibody or antigen-binding portion thereof, sufficient to reduce or ameliorate the severity and / or duration of a disease, e.g., cancer, or one or more symptoms thereof, prevent the progression of the disease, cause regression of the disease, prevent the recurrence, onset, development or progression of one or more symptoms associated with the disease, detect the disease, or enhance or improve the prophylactic or therapeutic effect(s) of another related therapeutic agent (e.g., a prophylactic or therapeutic agent) for a VISTA-mediated disease.
[0100] The actual amount administered, as well as the rate and time course of administration, will vary depending on the nature and severity of what is being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the composition, the method of administration, the dosing schedule, and other factors known to medical practitioners. Decisions regarding the prescription of treatment, e.g., dosage, etc., are within the responsibility of general physicians and other medical practitioners and may vary depending on the severity of the symptoms and / or progression of the disease being treated. Appropriate dosages of antibody molecules are well known in the art (Ledermann JA et al., 1991, Int. J. Cancer 47:659-664; Bagshawe KD et al., 1991, Antibody, Immunoconjugates and Radiopharmaceuticals 4:915-922). Specific dosages may be provided herein or specific dosages in the Physician's Desk Reference (2003) may be used as appropriate depending on the type of drug being administered. The therapeutically effective amount or suitable dose of an antibody molecule can be determined by comparing its in vitro activity and in vivo activity in an animal model. Methods for extrapolating effective dosages in mice and other experimental animals to humans are known. The exact dose will vary depending on a number of factors, including whether the antibody is prophylactic or therapeutic, the size and location of the area to be treated, the exact nature of the antibody (e.g., whole antibody, fragment), and the nature of any detectable label or other molecule attached to the antibody.
[0101] Typical antibody doses range from 100 μg to 1 g for systemic application and 1 μg to 1 mg for intradermal injection. An initial higher loading dose may be administered, followed by one or more lower doses. In some embodiments, the antibody is a whole antibody, e.g., of isotype IgG1 or IgG4. This is a single treatment dose for adult subjects, which may be adjusted proportionally for children and infants, and may also be adjusted proportionally to molecular weight for other antibody formats. At the discretion of the physician, treatment may be repeated at daily, twice-weekly, weekly, or monthly intervals. A subject's treatment schedule may vary depending on the pharmacokinetic and pharmacodynamic properties of the antibody composition, the route of administration, and the nature of the condition being treated.
[0102] Treatment may be regular, with the period between administrations being about 2 weeks or more, e.g., about 3 weeks or more, about 4 weeks or more, about once a month or more, about 5 weeks or more, or about 6 weeks or more. For example, treatment may be every 2-4 weeks or every 4-8 weeks. Treatment may occur before and / or after surgery and / or may be administered or applied directly to the anatomical site of a surgical or invasive procedure. Suitable formulations and routes of administration are described above.
[0103] In some embodiments, the anti-VISTA antibody molecules and antigen binding portions described herein may be administered as a subcutaneous injection.
[0104] In some embodiments, the therapeutic effect of an anti-VISTA antibody, or antigen-binding portion thereof, may last for several half-lives depending on the dose, for example, the therapeutic effect of a single dose of an anti-VISTA antibody, or antigen-binding portion thereof, may last for 1 month or more, 2 months or more, 3 months or more, 4 months or more, 5 months or more, or 6 months or more in a subject.
[0105] In some embodiments, the subject is a human, a non-human primate, a cynomolgus monkey, a pig, a horse, a cow, a dog, a cat, a guinea pig, a mouse, or a rat. In some embodiments, the subject is a human adult. In some embodiments, the subject is a human child.
[0106] Further provided herein is an anti-VISTA antibody or anti-VISTA antigen-binding portion, immunoconjugate, or pharmaceutical composition described herein for use in treating a disease or disorder (e.g., cancer).
[0107] Provided herein is an anti-VISTA antibody or anti-VISTA antigen-binding portion, immunoconjugate, or pharmaceutical composition described herein for use as a medicament.
[0108] Further provided herein is a multiplex immunohistochemistry (IHC) assay for quantifying the spatial proximity of VISTA+ and PSGL-1+ cells. In some embodiments, steps for performing such an assay are provided in Example 3. Under low pH conditions, such as those in the tumor microenvironment, VISTA becomes protonated, changing its charge, and possibly its shape, allowing for high affinity interaction with PSGL-1 on T cells. PSGL-1 has been shown to be a negative regulator of T cell activity, similar to PD-1. In some embodiments, the assay is used to identify tumor indications or subjects to be treated with an anti-VISTA antibody or anti-VISTA antigen binding moiety, immunoconjugate, or pharmaceutical composition described herein. Direct assessment of VISTA expression in tumors is considered a strong predictor, but insufficient predictor of the checkpoint involved, since VISTA expression is required. VISTA is strongly expressed in myeloid cells, regardless of whether VISTA is in its active protonated form or whether it physically interacts with PSGL-1. The assay described herein quantifies the amount of PSGL-1+ cells in physical proximity to VISTA+ cells within the tumor microenvironment based on multiplex IHC.
[0109] In some embodiments, the assay comprises assigning a VISTA:PSGL-1 proximity score to a tumor specimen from the subject, hi some embodiments, if the subject's tumor specimen has a VISTA:PSGL-1 proximity score above a defined threshold, the subject is treated with an anti-VISTA antibody or anti-VISTA antigen binding portion, immunoconjugate, or pharmaceutical composition described herein.
[0110] Provided herein are methods for treating a tumor in a subject, the methods comprising: (a) obtaining a VISTA:PSGL-1 proximity score for a tumor specimen from a subject, (i) obtaining images of tissues excised from a tumor specimen and immunohistochemically stained for VISTA and PSGL-1 expression in such a manner that VISTA stained cells can be distinguished from PSGL-1 stained cells; (ii) defining one or more regions of interest (ROIs) in the image that include tumor cells and tumor stroma, wherein substantially all of the tumor cells and tumor stroma in the image are contained within the defined ROIs; (iii) randomly creating a plurality of sub-regions of substantially the same shape and size across each defined ROI, each of the sub-regions defining an area large enough to include pairs of stained VISTA and PSGL-1 cells that are spatially proximal, and small enough to exclude pairs of stained VISTA and PSGL-1 cells that are not spatially proximal; and (iv) assigning or obtaining a VISTA:PSGL-1 proximity score to the tumor specimen by a step comprising: calculating the percentage of all sub-areas that are positive for both VISTA stained cells and PSGL-1 stained cells to generate a VISTA:PSGL-1 proximity score for the tumor specimen; (b) comparing the VISTA:PSGL-1 proximity score of the tumor specimen with a threshold VISTA:PSGL-1 proximity score; (c) classifying the tumor as biomarker positive or biomarker negative, where if the tumor specimen has a proximity score equal to or greater than the threshold proximity score, the tumor is classified as VISTA:PSGL-1 proximal biomarker positive, and if the tumor specimen has a score less than the threshold score, the tumor is classified as VISTA:PSGL-1 proximal biomarker negative; and (d) if the tumor is positive for the VISTA:PSGL-1 proximity biomarker, administering to the subject a therapeutically effective amount of an anti-VISTA antibody or antigen-binding portion, immunoconjugate, or pharmaceutical composition disclosed herein.
[0111] definition Unless otherwise stated, the terms used herein have the definitions commonly used in the art. Some terms are defined below, and additional definitions can be found in other parts of the detailed description.
[0112] The term "a" or "an" may refer to one or more of that entity, i.e., to a plurality of referents. Thus, the terms "a", "an", "one or more", and "at least one" are used interchangeably herein. Furthermore, the use of the indefinite article "a" or "an" to refer to "an element" does not exclude the possibility that a plurality of elements are present, unless the context requires that there is one and only one of that element.
[0113] Throughout this application, the term "about" is used to indicate that a value includes the inherent variation of error in the device or method used to determine the value or the variation that exists between samples measured. Unless otherwise stated or otherwise clear from the context, the term "about" means within 10% above or below the reported numerical value (except when such number is greater than 100% or less than 0% of the possible values). When used in conjunction with a range or series of values, the term "about" applies to the endpoints of the range or each of the values recited in that series, unless otherwise indicated. As used in this application, the terms "about" and "approximately" are used as equivalents.
[0114] As used herein, the term "sequence identity" refers to the degree to which two optimally aligned polynucleotide or polypeptide sequences are invariant throughout the region of alignment of residues, e.g., nucleotides or amino acids. The "percent identity" of an aligned segment of a test sequence and a reference sequence is the number of identical residues shared by the two aligned sequences divided by the total number of residues in the reference sequence segment, i.e., the entire reference sequence or a defined small portion of the reference sequence. The "percent identity" is the percentage identity multiplied by 100. The alignment program Clustal Omega, available at ebi.ac.uk / Tools / msa / clustalo, using default parameters, can be used to calculate the percentage identity. See Sievers et al., "Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega" (2011 October 11) Molecular systems biology 7:539. For the purpose of calculating identity for sequences, extensions such as tags are not included.
[0115] As used herein, the term "HCDR" refers to a heavy chain complementarity determining region. As used herein, the term "LCDR" refers to a light chain complementarity determining region.
[0116] As used herein, the term "conservative substitution" refers to the replacement of an amino acid with another amino acid that does not significantly and adversely change the functional activity. A preferred example of a "conservative substitution" is the replacement of an amino acid with another amino acid that has a value of 0 or greater in the following BLOSUM62 substitution matrix (see Henikoff & Henikoff, 1992, PNAS 89:10915-10919): TIFF2024543236000002.tif105164
[0117] "Antibody drug conjugate" and "immunoconjugate" refer to an antibody molecule, or antigen-binding portion thereof, e.g., an antibody derivative, bound to VISTA and conjugated to a cytotoxic, cytostatic and / or therapeutic agent.
[0118] The term "isolated molecule" (where the molecule is, for example, a polypeptide, polynucleotide, or antibody) refers to a molecule that, in terms of its origin or source of derivation, (1) is not associated with naturally associated components that accompany it in its natural state, (2) is substantially free of other molecules from the same species, (3) is expressed by cells from a different species, or (4) does not occur in nature. Thus, a molecule that is chemically synthesized or expressed in a cellular system different from the natural cell from which it originates is "isolated" from its naturally associated components. A molecule can also be rendered substantially free of naturally associated components by isolation, using purification techniques well known in the art. The purity or homogeneity of a molecule can be assayed by a number of means well known in the art. For example, the purity of a polypeptide sample can be assayed using polyacrylamide gel electrophoresis and staining the gel to visualize the polypeptide, using techniques well known in the art. For certain purposes, higher resolution may be obtained using HPLC or other means well known in the art for purification.
[0119] The term "epitope" refers to a portion of a molecule that an antibody molecule, or an antigen-binding portion thereof, can recognize and bind to at one or more of the antigen-binding regions of the antibody molecule. An epitope may consist of a defined region of a protein's primary, secondary, or tertiary structure, and includes the combination of secondary structural units or structural domains of a target that are recognized by the antigen-binding region of an antibody or an antigen-binding portion thereof. Similarly, an epitope may consist of a defined, chemically active surface grouping of molecules, such as amino acids or sugar side chains, and may have specific three-dimensional structural characteristics and specific charge characteristics. The term "antigenic epitope" as used herein is defined as a portion of a polypeptide to which an antibody molecule can specifically bind, as determined by any method known in the art, such as conventional immunoassays, antibody competitive binding assays, or by x-ray crystallography or related structure determination methods (e.g., nuclear magnetic resonance spectroscopy).
[0120] The term "potency" refers to a measure of biological activity and is defined as the IC of an antibody or antibody drug conjugate against the antigen VISTA to inhibit 50% of the activity measured in the VISTA activity assay described herein. 50 , E.C. 50 or as effective concentration.
[0121] The terms "inhibit" or "neutralize" as used herein with respect to the biological activity of the antibodies disclosed herein refer to the ability of the antibody to substantially antagonize, impede, prevent, suppress, slow down, destroy, eliminate, halt, reduce, or reverse the progression or severity of what is being inhibited, including, but not limited to, the biological activity or binding interaction of the antibody molecule to VISTA.
[0122] The section headings used herein are for organizational purposes only and should not be construed as limiting the subject matter described. All documents, or portions of documents, cited herein, including but not limited to patents, patent applications, articles, books, and papers, are expressly incorporated herein by reference in their entirety for any purpose. In the event that one or more of the incorporated documents or portions of documents defines a term in a manner that contradicts the definition of the term in this application, the definition appearing in this application shall control. However, the mention of any references, articles, publications, patents, patent publications, and patent applications cited herein is not, and should not be taken as, an admission or in any way suggesting that they are prior art or form part of the common general knowledge in any country in the world.
[0123] In the present description, any concentration range, percentage range, ratio range, or integer range should be understood to include any integer value within the stated range, and, where appropriate, fractions thereof (e.g., tenths and hundredths of an integer), unless otherwise indicated. The use of alternatives (e.g., "or") should be understood to mean either one, both, or any combination thereof of the alternatives. As used herein, the terms "include" and "comprise" are used synonymously. [Table 1] [Table 2] [Table 3] [Table 4] [Table 5] [Table 6] [Table 7] [Table 8] [Table 9] [Table 10] [Table 11]
Table 12
Table 13
Table 14
Table 15
Table 16
Table 17
Table 18
Table 19
Table 20
Table 21
Table 22
Table 23
Table 24
Table 25
[0124] The present disclosure will be further clarified by the following examples, which are intended to be merely illustrative of the disclosure and are not intended to be limiting in any way. EXAMPLES
[0125] Example 1. Generation and selection of parent pH-dependent anti-VISTA antibodies Fully human anti-VISTA antibodies were generated by a pH-selective enrichment strategy of a yeast-based platform library containing a highly diverse synthetic immune repertoire. Selection of the yeast-based platform library consisted of alternating positive enrichment rounds at pH 6.0 and negative selection rounds at pH 7.4 (Figure 1). The antibody-expressing yeast population was incubated with antigen at a specific pH, which was maintained during secondary labeling and sorting. The antigens used were recombinant extracellular domains of human VISTA tagged with Fc or His6. VISTA-FC is a dimer and VISTA-His6 is a monomer. The sequences of the VISTA antigen proteins are listed in Table 32.
[0126] 84 parent antibodies were initially isolated based on the testing steps shown in Figure 2. The binding characteristics of exemplary antibodies are shown in Figure 3.
[0127] The parental antibodies were extensively characterized using flow cytometry, Octet (ForteBio), and PSGL-1 / VISTA inhibition assays at pH 6.0 and pH 7.4 in primary human CD4 and human CD8 T cells (Figures 4A-C). These analyses revealed candidates that exhibited pH-dependent binding to endogenously expressed native VISTA on cells. Potent antagonists were identified by the PSGL-1 / VISTA inhibition assay at pH 6.0.
[0128] Eight parental antibodies were identified (Mab#1–Mab#8) and tested in vivo for efficacy in combination with an anti-mouse PD-1 antibody (rat mAb clone RMP1-14) in human VISTA knock-in (KI) mice inoculated with syngeneic MC-38 tumors. Female VISTA-KI mice were inoculated with 1 × 10 6 The tumor volume was approximately 60–80 mm. 3Mice were randomized (n=8 / cohort) when the antibody reached 100%. Antibodies were administered intraperitoneally twice weekly for 2 weeks at a total dose of 40 mg / kg (20 mg / kg each). The results are shown in Figures 5A-5H. Antibodies showed variable efficacy in combination, with a subset resulting in superior tumor rejection. Optimization of the parent antibodies was performed as described in Example 2.
[0129] Example 2. Optimization of pH-dependent anti-VISTA antibodies Optimization of eight parent antibodies for enhanced binding affinity and selectivity at pH 6.0 versus pH 7.4 was performed using the steps shown in Figure 6. Characterization and ranking of the optimized antibodies was based on the same in vitro and in vivo approaches as for the parent antibodies. Figures 7A-D show the results of the characterization of two representative anti-VISTA parent antibodies and their respective progeny.
[0130] Characterization of the optimized antibody resulted in the identification of antibody SNS-101, a pH-selective, high affinity, cynomolgus monkey cross-reactive IgG1 with superior biophysical and biochemical properties (see Table 4 for the amino acid sequence of SNS-101). The activity of SNS-101 was tested in an in vivo mouse tumor model. Female VISTA knock-in mice were injected with 1x10 6 The tumor volume was approximately 60–80 mm. 3 Mice were randomized (n=8 / cohort) upon reaching 100% CI 0.01 to 0.18. Antibodies were administered intraperitoneally twice weekly for 1 week at a total of 40 mg / kg (20 mg / kg each). The effects on tumor volume and percent survival are shown in Figures 8A and 8B, respectively. Groups were treated with (1) human and rat IgG controls, (2) human IgG control and rat anti-mPD-1, or (3) rat anti-mPD-1 and anti-VISTA.
[0131] SNS-101 has a monovalent affinity (K D ) is 0.218 nM, and the monovalent affinity (K D) was 132 nM (or "non-binding"). Furthermore, SNS-101 inhibits PSGL-1 / VISTA interaction by more than 95%, induces tumor rejection in more than 40% of animals in syngeneic tumor models as monotherapy, and induces tumor rejection in approximately 50% of animals in syngeneic tumor models as combination therapy.
[0132] Example 3. Multiplex immunohistochemistry (IHC) assay to quantify spatial proximity of PSGL-1 / VISTA in tumor cells Multiplex IHC. Formalin-fixed paraffin-embedded tissue microarrays were purchased from US Biomax (Rockville, MD) and baked for 30 min at 60° C. Slides were then dewaxed using standard IHC protocols and antigen retrieved in Tris-EDTA, pH 9 (Abcam, Waltham, MA) for 20 min at 95° C. in a Decloaker (Biocare Medical, Pacheco, CA) before loading onto a Biocare intelliPATH FLX® automated stainer using TBS Automation Wash Buffer (Biocare) for the wash steps. [Table 33]
[0133] Endogenous peroxidase was blocked with 3% H2O2 for 5 min, followed by Background Punisher protein block (Biocare) for 5 min. The first primary antibody (position 1) was added for 30 min, followed by the secondary antibody for 20 min and the tertiary TSA amplification reagent (OPAL fluor, Akoya Biosciences, Menlo Park, CA) for 15 min. All blocking and staining steps were performed at room temperature. The primary and secondary antibodies were removed with a Decloaker containing Tris-EDTA at 95°C for 20 min, and the process was repeated with the second primary antibody (position 2). Slides were removed from the autostainer, stained with Spectral DAPI (Akoya) for 5 min, rinsed for 5 min, and coverslipped with Prolong Gold Antifade reagent (Invitrogen / Life Technologies, Grand Island, NY).
[0134] Imaging tests. Slides were stored in the dark at room temperature for 24 hours and then imaged on a PhenoImager™ HT Automated Quantitative Pathology Imaging System (Akoya) and exported to QPTIFF files for image analysis.
[0135] Image analysis. TMA (tissue microarray) segmentation and cell analysis of images were performed using HALO image analysis software (v3.4, Indica Labs, Corrales, NM). After visualizing all cells based on nuclear and cytoplasmic staining using the HighPlex FL v4.1.3 analysis module, the software measured the mean fluorescence intensity of pixels in each section. A mean intensity threshold above background was used to determine positivity for each fluorochrome, thereby defining cells as either positive or negative for each marker. For each marker, quality control of fluorescent staining quality and confirmation of marker threshold cutoffs were performed using DAB staining, which was re-evaluated by a pathologist on adjacent / nearby sections of the TMA.
[0136] Positive cell data was used to define single and double positive populations and spatial analysis was performed on each TMA core. Proximity analysis was performed with the HALO spatial analysis module to determine the number and average distance of PSGL-1+ cells within 100 μm of VISTA+ cells. To qualitatively view the proximity of PSGL-1 to VISTA, a histogram was generated by dividing the 100 μm distance around VISTA+ cells into 10 μm wide bands to visually represent the average number of PSGL-1 cells within each band.
[0137] Representative images and data analysis results are shown in Figures 9A-L.
[0138] Example 4. Cytokine release profile of SNS-101 in an ex vivo system mimicking human blood circulation Cancer immunotherapy drugs can produce immune-mediated adverse events (AEs), including CRS (Shimabukuro-Vornhagen et al., J Immunother Cancer. 2018;6(1):56). On-target and off-tumor activation of myeloid cells (e.g., monocytes) has been implicated as a factor in the development of these immune-mediated AEs (Mortha et al., Front Immunol. 2018;9:191). Antibodies that bind to VISTA at physiological pH (7.4) are significantly more likely to induce dose-limiting toxicities such as CRS and are cleared early from the circulation via target-mediated drug elimination (TMDD), reducing the likelihood of reaching effective drug occupancy levels. Of the several non-pH-selective antibodies in clinical development, JNJ-61610588 (now CI-8993) induced dose-limiting, on-target CRS and exhibited TMDD at sub-therapeutic doses (Curis Inc., Corporate Presentation, Jefferies Global Healthcare Conference, June 9, 2022, available at URL filecache.investorroom.com / mr5ir_curis / 225 / 2022-06_Curis%20Corporate%20Presentation.pdf).
[0139] The circulating whole blood loop assay is superior to standard plate assays in that it exhibits significantly lower background cytokine release, which translates into increased assay sensitivity and has been shown to be a powerful human-based in vitro assay for predicting CRS (Fletcher et al., Int Immunopharmacol. 2018;54:1-11). Using this assay, we tested whether the selective pH-dependent binding properties of SNS-101 reduce CRS risk compared to JNJ (antibody JNJ-61610588 variable regions cloned onto a human IgG1 backbone) (Figure 10A-E).
[0140] Six healthy donors were included in the study. Plasma samples were taken at baseline and 4 hours after ID.Flow. The calculated lower limit of quantification (LLOQ) and upper limit of quantification (ULOQ) are marked with dotted lines. Log 10 Paired Student's t-tests were performed on transformed values (values below the LLOQ were brought up to the LLOQ, values above the ULOQ were set to the ULOQ) followed by Holm-Sidak correction for multiple comparisons; controls alemtuzumab (positive control), anti-CD28 (positive control), and cetuximab (negative isotype control) were compared to PBS, JNJ- and SNS-101-treated samples were compared to formulation buffer, and selected JNJ- and SNS-101-treated samples were compared to each other. Statistical significance was determined. * Displayed by. * p < 0.05; ** p < 0.01; *** p<0.001; **** p<0.0001. Comparisons that did not reach statistical significance are not shown. The controls alemtuzumab, anti-CD28, and cetuximab showed the expected effects on cytokine release.
[0141] The concentrations of IFNγ, IL-6, and TNFα in SNS-101-treated samples were comparable to the lower concentrations of formulation buffer (1 μg / mL and 10 μg / mL). SNS-101 at 100 μg / mL caused a mild induction of IFNγ and TNFα that did not reach statistical significance. SNS-101-treated samples showed elevated concentrations of IL-8 at all concentrations tested, and at 100 μg / mL, this induction was statistically significant compared to formulation buffer. In contrast, JNJ caused a statistically significant increase in the concentrations of IFNγ, IL-6, IL-8, and TNFα at all concentrations tested compared to formulation buffer. The concentrations of IL-2 were below the LLOQ for both JNJ and SNS-101 at all concentrations tested. The lowest concentration of JNJ tested produced statistically significantly higher (100-fold higher) concentrations of IFNγ, TNFα, and IL-8 compared to the highest concentration of SNS-101 tested. In summary, SNS-101 exhibits a favorable pro-inflammatory profile compared to JNJ.
[0142] The percentage of CD83+ monocytes (FIG. 10F), CD83 MFI (median) (FIG. 10G), CD69+ NK cells (FIG. 10H), and CD69 MFI (median) (FIG. 10I) were measured. Blood was collected at baseline and 4 hours after ID.Flow, followed by flow cytometry analysis. The dotted line indicates the mean of the formulation buffer group. Values were subjected to paired Student's t-tests followed by Holm-Sidak correction for multiple comparisons; controls alemtuzumab, anti-CD28, and cetuximab were compared to PBS, and JNJ- and SNS-101-treated samples were compared to formulation buffer; * p < 0.05; ** p < 0.01; *** p<0.001; comparisons that did not reach statistical significance are not shown.
[0143] All concentrations of JNJ and the highest concentration of SNS-101 significantly activated monocytes compared to formulation buffer, whereas other concentrations of SNS-101 only activated a portion of monocytes from donors (Figures S10F, S10G). CD83 MFI (monocytes) was generally higher in JNJ-treated samples than in SNS-101-treated samples (Figures S10F, S10G).
[0144] JNJ induced significant NK cell activation (CD69) at all concentrations tested, whereas SNS-101 induced significant induction of NK cell activation only at the highest concentration tested (Figure 10H, I), although this did not reach significance levels compared to formulation buffer (Figure 10I).
[0145] Example 5. Pharmacokinetic profile of SNS-101 in cynomolgus monkeys The objective of the non-GLP exploratory study was to determine the toxicity and PK profile of pH-sensitive anti-VISTA antibody SNS-101 in cynomolgus monkeys after a single intravenous infusion over 1 hour, and to evaluate the persistence, delayed onset, or reversibility of any changes after a 28-day observation period (non-pH-sensitive anti-VISTA antibody, h26A, was included as a positive control). Groups of monkeys (n=4; 2 / sex) were administered SNS-101 and h26A as a single 1-hour intravenous infusion using a temporary catheter. The PK profile of SNS-101 was evaluated in male and female cynomolgus monkeys at doses of 1 mg / kg, 10 mg / kg, and 100 mg / kg (Figures 11A and 11B). Additionally, the comparator, non-pH-sensitive antibody h26A, was also tested at 10 mg / kg. Figure 11A shows the resulting PK profiles of SNS-101 and the non-pH-selective antibody h26A.
[0146] H26A showed significant TMDD and was at the lower limit of quantification after 48 hours. In contrast, dose-proportional exposure of SNS-101 was observed following a single 1-hour IV infusion of 1, 10, or 100 mg SNS-101 / kg body weight in monkeys. Although only two animals per sex were evaluated at each dose, no obvious differences were observed in the PK profiles of male versus female animals. The mean concentration-time profiles and PK parameter estimates for male and female animals were similar within each dose group, so data from both sexes were combined (Figure 11B).
[0147] In summary, plasma CL, T 1 / 2λ and V SS These findings suggest a linear disposition profile of SNS-101 in monkeys, which is consistent with the absence of TMDD.
[0148] Example 6. SNS-101 shows strong activity in combination with anti-PD-1 antibody in the MC-38 model of human VISTA knock-in mice, increasing CD8+ T cells We investigated the therapeutic potential of SNS-101 in the MC38 syngeneic tumor model in human VISTA knock-in mice. MC-38 is a colon adenocarcinoma model isolated from colon tumors in C57BL / 6 mice after chronic exposure to the carcinogen DMH (1,2-dimethylhydrazine dihydrochloride). To minimize the potential for anti-SNS-101 neutralizing antibodies and maximize the interaction with mouse Fc receptors on immune cells, we grafted SNS-101 onto a mouse IgG2a scaffold, which is equivalent to human IgG1 (SNS-101-m2).
[0149] The goal of this study was to evaluate the anti-tumor activity of the anti-VISTA antibody SNS-101 in combination with an anti-mouse PD-1 antibody in established MC-38 tumors. Mice were treated with either 1 mg / kg and 5 mg / kg of the anti-mouse PD-1 antibody (RMP1-14) alone or in combination with 3 mg / kg, 10 mg / kg, and 30 mg / kg of SNS-101-m2, respectively (Figures 12A and 12B).
[0150] 1 × 10 female VISTA knock-in mice 6 The tumor volume was approximately 60–80 mm. 3 Mice were randomized (n=12 / cohort) when the tumor reached 100%. Antibodies were administered intraperitoneally twice weekly for anti-mouse PD-1 antibody (RMP1-14) or three times weekly for SNS-101-m2. The effect on tumor volume is shown in Figure 12A. Groups were treated with (1) mouse and rat IgG control, (2) IgG control mouse and rat anti-mPD-1, or (3) rat anti-mPD-1 and anti-VISTA.
[0151] The 1 mg / kg anti-PD-1 treatment group did not induce statistically significant tumor growth inhibition compared to isotype control-treated animals, however, the combination of 1 mg / kg anti-PD-1 with 10 mg / kg and 30 mg / kg SNS-101-m2 induced significant tumor growth inhibition (P values 0.002 and 0.004, respectively; Mann-Whitney unpaired t-test).
[0152] On day 17 after treatment, single cell suspensions were generated from tumor extracts by physical and enzymatic dissociation. Cell concentrations were determined and measured at 1 × 10 per sample. 6 The cells were subjected to viability, αCD45, and αCD8 staining in V-bottom 96-well plates. Analytical flow cytometry analysis determined the frequency of CD8+ cells in the single live CD45+ population (Figure 12B). The 30mg / kg SNS-101-m2 + anti-mouse PD-1 group had a significantly higher frequency of CD8+ population than all other groups except the 10mg / kg SNS-101-m2 + anti-mouse PD-1 group (p<0.05, p<0.01, p<0.001, p<0.0001).
[0153] A Bio-Rad Bio-Plex 200 instrument was used to quantify cytokines in plasma samples isolated from mice on day 17, with validation procedures and instrument calibration performed as described in the instrument manual prior to running the assays. The assays used to measure the analytes were: Bio-Plex Pro Mouse Cytokine 23-plex Assay (Bio-Rad Catalog No. #M60009RDPD), Bio-Plex Pro Mouse Chemokine Panel 31-plex Assay (Bio-Rad Catalog No. #12009159), and Bio-Plex Pro Mouse Th17 Cytokine 10-plex Assay (Bio-Rad Catalog No. #12010828). The assays were performed according to the kit manual.
[0154] To visualize the data, analyte levels were first log-transformed and then the arithmetic mean of each treatment group was obtained. Finally, Z-scores were calculated for group means and used to generate heatmaps (R Pheatmap package) (Figure 12C). Dendrograms were generated using hierarchical clustering based on Euclidean distance between cytokine profiles of different groups. As shown in Figure 12C, both families of cytokines with elevated and decreased levels were identified in the groups treated with SNS-101-m2 and anti-mouse PD-1 (5, 6) compared to either the untreated control group (1) or the group receiving anti-mouse PD-1 alone (2). For statistical analysis, analysis of variance (ANOVA) was performed on the log-transformed cytokine data with false discovery rate (FDR) correction for multiple comparisons. Follow-up analyses were performed to determine whether the FDR significantly adjusted p-values (p adj <0.05) and were performed using Tukey's HSD test (R package) (see Tables 34A-34C). [Table 34A] [Table 34B] [Table 34C]
[0155] Example 7. SNS-101 shows robust activity as a single agent and in combination with anti-PD-1 in the MB49 model of human VISTA knock-in mice The therapeutic potential of SNS-101 was investigated in the MB49 syngeneic tumor model in human VISTA knock-in mice. MB49 cells (urothelial carcinoma) were derived from C57BL / 6 mice in which primary bladder cells were cultured after exposure to DMBA (7,12-dimethylbenz[a]anthracene) for 24 hours (White-Gilbertson et al.,Bladder(San Franc).2016;3(1):e22). MB49 has a cold tumor phenotype and is CD8 + and CD4 + It is believed that the level of T cell infiltration in mice is very low (<3%) and there is a significant presence of immunosuppressive myeloid populations (~65%). To minimize the possibility of anti-SNS-101 neutralizing antibodies and maximize the interaction with mouse Fc receptors on immune cells, we grafted SNS-101 onto a scaffold of mouse IgG2a, the human IgG1 equivalent (SNS-101-m2).
[0156] The goal of this study was to evaluate the anti-tumor activity of the anti-VISTA antibody SNS-101 alone and in combination with different doses of anti-mouse PD-1 in a dose-response fashion (similar to MC38). Mice were treated with either 1 mg / kg and 5 mg / kg of the anti-mouse PD-1 antibody (RMP1-14) alone or in combination with 3 mg / kg, 10 mg / kg, and 30 mg / kg of SNS-101-m2, respectively (Figures 12D-G).
[0157] 1 × 10 male VISTA knock-in mice 6 The tumor volume was approximately 70–100 mm. 3 Mice were randomized (n=14 / cohort) when the tumor reached 100%. Antibodies were administered intraperitoneally twice weekly for anti-mouse PD-1 antibody (RMP1-14) or three times weekly for SNS-101-m2. The effect on tumor volume is shown for individual mice (FIGS. 12D, 12E) and for the combined treatment groups (FIGS. 12F, 12G). Groups were treated with (1) mouse and rat IgG control, (2) IgG control mouse and rat anti-mPD-1, or (3) rat anti-mPD-1 and anti-VISTA.
[0158] In this in vivo study, anti-VISTA SNS-101-m2 was administered for 2 weeks either alone (3 mg / kg, 10 mg / kg, or 30 mg / kg) or in combination with anti-mouse PD-1 (1 mg / kg or 5 mg / kg). Antibody treatment was well tolerated and no significant body weight changes were observed. Anti-mPD-1 at 1 mg / kg and 5 mg / kg resulted in substantial tumor growth inhibition (59%, P=0.0001; 55%, P=0.0003). Monotherapy with SNS-101 at 3 mg / kg, 10 mg / kg, and 30 mg / kg showed tumor growth inhibition (46%, 23%, and 43%), but only reached statistical significance at the lowest and highest doses, respectively. Combinations of SNS-101-m2 at 3 mg / kg, 10 mg / kg and 30 mg / kg with either 1 mg / kg or 5 mg / kg anti-mouse PD-1 resulted in statistically significant tumor growth inhibition compared to the isotype control group (71%, 64%, 56%, 83%, 73% and 73%, all P<0.0001). However, only the combination of SNS-101-m2 at 3 mg / kg and anti-mouse PD-1 at 5 mg / kg resulted in statistically significant tumor growth inhibition compared to the 5 mg / kg anti-mPD-1 group (83%, P<0.02). The other combinations induced tumor growth inhibition but did not reach statistical significance compared to the corresponding anti-mPD-1 treated groups.
[0159] A Bio-Rad Bio-Plex 200 instrument was used to quantify cytokines in plasma samples isolated from mice on day 15, with validation procedures and instrument calibration performed as described in the instrument manual prior to running the assays. The assays used to measure the analytes were: Bio-Plex Pro Mouse Cytokine 23-plex Assay (Bio-Rad Catalog No. #M60009RDPD), Bio-Plex Pro Mouse Chemokine Panel 31-plex Assay (Bio-Rad Catalog No. #12009159), and Bio-Plex Pro Mouse Th17 Cytokine 10-plex Assay (Bio-Rad Catalog No. #12010828). The assays were performed according to the kit manual.
[0160] To visualize the data, analyte levels were first log-transformed and then the arithmetic mean of each treatment group was obtained. Finally, Z-scores were calculated for group means and used to generate heatmaps (R Pheatmap package) (Figure 12H). Dendrograms were generated using hierarchical clustering based on Euclidean distance between cytokine profiles of different groups. As shown in Figure 12H, both families of cytokines with elevated and decreased levels were identified in the groups treated with SNS-101-m2 and anti-mouse PD-1 (5, 6) compared to either the untreated control group (1) or the groups that received either SNS-101-m2 (4) or anti-mouse PD-1 alone (2, 3). For statistical analysis, analysis of variance (ANOVA) was performed on the log-transformed cytokine data with false discovery rate (FDR) correction for multiple comparisons. Follow-up analyses were performed to determine whether the FDR significantly adjusted p-values (p adj <0.05) and were performed using Tukey's HSD test (R package) (see Tables 35A-35C). [Table 35A] [Table 35B] [Table 35C]
[0161] Example 8. Cytokine release profile of SNS-101 in an in vivo cytokine release syndrome model The cytokine release profile of SNS-101 was examined in a humanized mouse model. BRGSF-HIS mice (reconstituting a functional human immune system) were generated as previously described (Lopez-Lastra et al. Blood Adv, 2017, 1(10):601-614). Circulating human CD45 + BRGSF-HIS mice were quality controlled (QC) by assessing cells and specific immune cell subsets. Human myeloid cell development was enhanced in BRGSF-HIS QC (n=60) mice by intraperitoneal (IP) injection of hFlt3L-Fc. SNS-101 was compared to JNJ (antibody JNJ-61610588 variable regions cloned onto a human IgG1 backbone), a clinical-stage, non-pH selective anti-VISTA antibody. Serum was collected at the indicated time points (hours post-injection).
[0162] Sera were collected from six mice at each time point, and cytokines were quantified by multiplex bead-based assay. The results are shown in Figure 13. The positive control anti-CD3 antibody (OKT3) efficiently induced CRS. JNJ induced IL-6, IL-10, CCL-2, CCL-5, CXCL-8, CXCL-10, IFN-γ, TNF-α, and IL-1RA in a dose-dependent manner, whereas SNS-101 only weakly induced CCL-5. These results suggest that SNS-101 has a significantly lower risk of inducing CRS than the non-pH-dependent anti-VISTA antibody.
[0163] Example 9. SNS-101 inhibits the interaction between VISTA and other potential binding partners Peptide array binding analysis showed that SNS-101 blocks the PSGL-1:VISTA protein interface. Figures 14A and 14B show a comparison of the putative binding interface of SNS-101 (gray):VISTA (Figure 14A; defined by peptide array (PepScan) binding) (Johnston et al. Nature 574, 565-570 (2019)) aligned to the positions of the five key histidine (His) residues involved in PSGL-1 (dark grey) binding, as well as residues proposed to be involved in binding with putative partners VSIG-3 (light grey) and LRIG-1 (medium grey) (Thakkar et al. J Immunother Cancer, 2022, 10: e003382) (Figure 14B). The human VISTA model from AlphaFold was used.
[0164] Competition experiments were performed at pH 6.0 using dilutions of SNS-101 or isotype control pre-incubated with 1 mg / ml biotinylated hVISTA-Fc prior to addition to coated ELISA wells. The results are shown in Figure 15. SNS-101 inhibited the interaction between VISTA and PSGL-1 and all other potential partners (VSIG-3, VSIG-8, syndecan-2, and LRIG-1) with an IC of less than 7 nM. 50 was inhibited.
[0165] Example 10. Crystal structure of hVISTA:SNS-101 Fab complex The X-ray crystal structure of human VISTA:human SNS-101 Fab antibody fragment complex (VISTA:Fab SNS-101 complex) was generated. Diffraction data for the VISTA:Fab SNS-101 complex were collected at SWISS LIGHT SOURCE (SLS, Villigen, Switzerland). The structure was solved and refined using data from STARANISO with anisotropic resolution cutoffs of 2.48 Å, 2.80 Å, and 3.30 Å. The overall resolution of uniformly scaled data is 2.97 Å (I / sigI ≥ 1.2 in the outermost shell from 3.02 to 2.97 Å).
[0166] The structure of the VISTA:Fab SNS-101 complex at 2.59 Å resolution is shown in Figures 14C-F.
[0167] hVISTA is represented as a molecular surface (Figure 14D, F) and SNS-101 is represented as a ribbon cartoon (Figure 14C, E). The blocked surface of VISTA in the presence of SNS-101 is shaded in light grey, while the unblocked portion is shaded in dark grey. The dark and light grey shaded ribbons represent the light and heavy chains of SNS-101, respectively. All amino acids of hVISTA that are within 4 Å (Figure 14C, D) or 6 Å (Figure 14E, F) of any portion of SNS-101 were used to generate the blocked surface.
[0168] FIG. 14G shows the interacting amino acid residues of PSGL-1, VSIG-3 and LRIG-1 highlighted on the VISTA structure and shows a comparison of the blocking site of SNS-101 with the interacting amino acid residues of PSGL-1, VSIG-3 and LRIG-1.
[0169] Tables 35 and 36 provide a list of amino acid residues in hVISTA that are blocked in the presence of SNS-101 Fab. The underlined amino acid residues are located within 4 Å (Table 36) or within 6 Å (Table 37) of any part of the VISTA:SNS-101 interface. The non-underlined amino acid residues are located more than 4 Å or 6 Å away from any part of the VISTA:SNS-101 interface. However, these residues have been included in the tables to indicate amino acid regions that may be blocked in the presence of SNS-101. [Table 36] [Table 37]
[0170] Numbered embodiments Without limiting the scope of the appended claims, this disclosure describes the following numbered embodiments:
[0171] 1. A V-domain immunoglobulin inhibitor of T cell activation (VISTA) antibody or an antigen-binding portion thereof, comprising a heavy chain variable (VH) region and a light chain variable (VL) region, wherein: (a) the VH domain amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 54, an HCDR2 comprising SEQ ID NO: 55, and an HCDR3 comprising SEQ ID NO: 56, and the VL domain amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 57, an LCDR2 comprising SEQ ID NO: 58, and an LCDR3 comprising SEQ ID NO: 59; or (b) the VH domain amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 60, an HCDR2 comprising SEQ ID NO: 61, and an HCDR3 comprising SEQ ID NO: 56, and the VL domain amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 57, an LCDR2 comprising SEQ ID NO: 58, and an LCDR3 comprising SEQ ID NO: 59; or (c) the VH domain amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 62, an HCDR2 comprising SEQ ID NO: 63, and an HCDR3 comprising SEQ ID NO: 56, and the VL domain amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 57, an LCDR2 comprising SEQ ID NO: 58, and an LCDR3 comprising SEQ ID NO: 59; or (d) the VH domain amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 64, an HCDR2 comprising SEQ ID NO: 65, and an HCDR3 comprising SEQ ID NO: 66, and the VL domain amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 57, an LCDR2 comprising SEQ ID NO: 67, and an LCDR3 comprising SEQ ID NO: 68; or (e) the VH domain amino acid sequence comprises an HCDR1 comprising SEQ ID NO:69, an HCDR2 comprising SEQ ID NO:70, and an HCDR3 comprising SEQ ID NO:56, and the VL domain amino acid sequence comprises an LCDR1 comprising SEQ ID NO:57, an LCDR2 comprising SEQ ID NO:67, and an LCDR3 comprising SEQ ID NO:71; or (f) the VH domain amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 60, an HCDR2 comprising SEQ ID NO: 61, and an HCDR3 comprising SEQ ID NO: 72, and the VL domain amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 57, an LCDR2 comprising SEQ ID NO: 58, and an LCDR3 comprising SEQ ID NO: 68; or (g) the VH domain amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 73, an HCDR2 comprising SEQ ID NO: 65, and an HCDR3 comprising SEQ ID NO: 74, and the VL domain amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 57, an LCDR2 comprising SEQ ID NO: 58, and an LCDR3 comprising SEQ ID NO: 71; or (h) the VH domain amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 64, an HCDR2 comprising SEQ ID NO: 75, and an HCDR3 comprising SEQ ID NO: 66, and the VL domain amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 57, an LCDR2 comprising SEQ ID NO: 76, and an LCDR3 comprising SEQ ID NO: 68; or (i) the VH domain amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 64, an HCDR2 comprising SEQ ID NO: 65, and an HCDR3 comprising SEQ ID NO: 77, and the VL domain amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 57, an LCDR2 comprising SEQ ID NO: 78, and an LCDR3 comprising SEQ ID NO: 68; or (j) the VH domain amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 60, an HCDR2 comprising SEQ ID NO: 75, and an HCDR3 comprising SEQ ID NO: 56, and the VL domain amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 57, an LCDR2 comprising SEQ ID NO: 58, and an LCDR3 comprising SEQ ID NO: 68; or (k) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 54, an HCDR2 comprising SEQ ID NO: 65, and an HCDR3 comprising SEQ ID NO: 79, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 80, an LCDR2 comprising SEQ ID NO: 58, and an LCDR3 comprising SEQ ID NO: 68; or (l) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 81, an HCDR2 comprising SEQ ID NO: 82, and an HCDR3 comprising SEQ ID NO: 83, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 84, an LCDR2 comprising SEQ ID NO: 85, and an LCDR3 comprising SEQ ID NO: 86; or (m) the VH domain amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 87, an HCDR2 comprising SEQ ID NO: 88, and an HCDR3 comprising SEQ ID NO: 83, and the VL domain amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 84, an LCDR2 comprising SEQ ID NO: 85, and an LCDR3 comprising SEQ ID NO: 86; or (n) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 89, an HCDR2 comprising SEQ ID NO: 90, and an HCDR3 comprising SEQ ID NO: 83, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 84, an LCDR2 comprising SEQ ID NO: 85, and an LCDR3 comprising SEQ ID NO: 86; or (o) the VH domain amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 91, an HCDR2 comprising SEQ ID NO: 92, and an HCDR3 comprising SEQ ID NO: 83, and the VL domain amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 84, an LCDR2 comprising SEQ ID NO: 85, and an LCDR3 comprising SEQ ID NO: 86; or (p) the VH domain amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 93, an HCDR2 comprising SEQ ID NO: 94, and an HCDR3 comprising SEQ ID NO: 95, and the VL domain amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 96, an LCDR2 comprising SEQ ID NO: 85, and an LCDR3 comprising SEQ ID NO: 97; or (q) the VH domain amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 98, an HCDR2 comprising SEQ ID NO: 99, and an HCDR3 comprising SEQ ID NO: 100, and the VL domain amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 96, an LCDR2 comprising SEQ ID NO: 101, and an LCDR3 comprising SEQ ID NO: 102; or (r) the VH domain amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 103, an HCDR2 comprising SEQ ID NO: 104, and an HCDR3 comprising SEQ ID NO: 105, and the VL domain amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 96, an LCDR2 comprising SEQ ID NO: 106, and an LCDR3 comprising SEQ ID NO: 107; or (s) the VH domain amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 108, an HCDR2 comprising SEQ ID NO: 94, and an HCDR3 comprising SEQ ID NO: 105, and the VL domain amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 109, an LCDR2 comprising SEQ ID NO: 85, and an LCDR3 comprising SEQ ID NO: 110; or (t) the VH domain amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 111, an HCDR2 comprising SEQ ID NO: 94, and an HCDR3 comprising SEQ ID NO: 112, and the VL domain amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 96, an LCDR2 comprising SEQ ID NO: 85, and an LCDR3 comprising SEQ ID NO: 113; or (u) the VH domain amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 87, an HCDR2 comprising SEQ ID NO: 94, and an HCDR3 comprising SEQ ID NO: 114, and the VL domain amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 115, an LCDR2 comprising SEQ ID NO: 85, and an LCDR3 comprising SEQ ID NO: 116; or (v) the VH domain amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 93, an HCDR2 comprising SEQ ID NO: 90, and an HCDR3 comprising SEQ ID NO: 117, and the VL domain amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 118, an LCDR2 comprising SEQ ID NO: 85, and an LCDR3 comprising SEQ ID NO: 86; or (w) the VH domain amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 119, an HCDR2 comprising SEQ ID NO: 120, and an HCDR3 comprising SEQ ID NO: 121, and the VL domain amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 57, an LCDR2 comprising SEQ ID NO: 58, and an LCDR3 comprising SEQ ID NO: 122; or (x) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 123, an HCDR2 comprising SEQ ID NO: 124, and an HCDR3 comprising SEQ ID NO: 125, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 126, an LCDR2 comprising SEQ ID NO: 127, and an LCDR3 comprising SEQ ID NO: 128; or (y) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 123, an HCDR2 comprising SEQ ID NO: 124, and an HCDR3 comprising SEQ ID NO: 129, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 57, an LCDR2 comprising SEQ ID NO: 58, and an LCDR3 comprising SEQ ID NO: 130; or (z) the VH domain amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 131, an HCDR2 comprising SEQ ID NO: 132, and an HCDR3 comprising SEQ ID NO: 133, and the VL domain amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 126, an LCDR2 comprising SEQ ID NO: 134, and an LCDR3 comprising SEQ ID NO: 135; or (aa) the VH domain amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 131, an HCDR2 comprising SEQ ID NO: 132, and an HCDR3 comprising SEQ ID NO: 136, and the VL domain amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 57, an LCDR2 comprising SEQ ID NO: 58, and an LCDR3 comprising SEQ ID NO: 137; or (bb) the VH domain amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 54, an HCDR2 comprising SEQ ID NO: 138, and an HCDR3 comprising SEQ ID NO: 139, and the VL domain amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 57, an LCDR2 comprising SEQ ID NO: 58, and an LCDR3 comprising SEQ ID NO: 140; or (cc) the antibody or antigen-binding portion thereof, wherein the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 81, an HCDR2 comprising SEQ ID NO: 82, and an HCDR3 comprising SEQ ID NO: 141, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 142, an LCDR2 comprising SEQ ID NO: 143, and an LCDR3 comprising SEQ ID NO: 144.
[0172] 2. (a) the VH region amino acid sequence comprises SEQ ID NO:1 and the VL region amino acid sequence comprises SEQ ID NO:2; or (b) the VH region amino acid sequence comprises SEQ ID NO:3 and the VL region amino acid sequence comprises SEQ ID NO:2; or (c) the VH region amino acid sequence comprises SEQ ID NO:4 and the VL region amino acid sequence comprises SEQ ID NO:2; or (d) the VH region amino acid sequence comprises SEQ ID NO:5 and the VL region amino acid sequence comprises SEQ ID NO:6; or (e) the VH region amino acid sequence comprises SEQ ID NO:7 and the VL region amino acid sequence comprises SEQ ID NO:8; or (f) the VH region amino acid sequence comprises SEQ ID NO:9 and the VL region amino acid sequence comprises SEQ ID NO:10; or (g) the VH region amino acid sequence comprises SEQ ID NO:11 and the VL region amino acid sequence comprises SEQ ID NO:12; or (h) the VH region amino acid sequence comprises SEQ ID NO:13 and the VL region amino acid sequence comprises SEQ ID NO:14; or (i) the VH region amino acid sequence comprises SEQ ID NO: 15 and the VL region amino acid sequence comprises SEQ ID NO: 16; or (j) the VH region amino acid sequence comprises SEQ ID NO: 17 and the VL region amino acid sequence comprises SEQ ID NO: 18; or (k) the VH region amino acid sequence comprises SEQ ID NO: 19 and the VL region amino acid sequence comprises SEQ ID NO: 20; or (l) the VH region amino acid sequence comprises SEQ ID NO:21 and the VL region amino acid sequence comprises SEQ ID NO:22; or (m) the VH region amino acid sequence comprises SEQ ID NO:23 and the VL region amino acid sequence comprises SEQ ID NO:22; or (n) the VH region amino acid sequence comprises SEQ ID NO:24 and the VL region amino acid sequence comprises SEQ ID NO:22; or (o) the VH region amino acid sequence comprises SEQ ID NO:25 and the VL region amino acid sequence comprises SEQ ID NO:22; or (p) the VH region amino acid sequence comprises SEQ ID NO:26 and the VL region amino acid sequence comprises SEQ ID NO:27; or (q) the VH region amino acid sequence comprises SEQ ID NO:28 and the VL region amino acid sequence comprises SEQ ID NO:29; or (r) the VH region amino acid sequence comprises SEQ ID NO: 30 and the VL region amino acid sequence comprises SEQ ID NO: 31; or (s) the VH region amino acid sequence comprises SEQ ID NO: 32 and the VL region amino acid sequence comprises SEQ ID NO: 33; or (t) the VH region amino acid sequence comprises SEQ ID NO: 34 and the VL region amino acid sequence comprises SEQ ID NO: 35; or (u) the VH region amino acid sequence comprises SEQ ID NO: 36 and the VL region amino acid sequence comprises SEQ ID NO: 37; or (v) the VH region amino acid sequence comprises SEQ ID NO:38 and the VL region amino acid sequence comprises SEQ ID NO:39; or (w) the VH region amino acid sequence comprises SEQ ID NO: 40 and the VL region amino acid sequence comprises SEQ ID NO: 41; or (x) the VH region amino acid sequence comprises SEQ ID NO: 42 and the VL region amino acid sequence comprises SEQ ID NO: 43; or (y) the VH region amino acid sequence comprises SEQ ID NO: 44 and the VL region amino acid sequence comprises SEQ ID NO: 45; or (z) the VH region amino acid sequence comprises SEQ ID NO: 46 and the VL region amino acid sequence comprises SEQ ID NO: 47; or (aa) the VH region amino acid sequence comprises SEQ ID NO: 48 and the VL region amino acid sequence comprises SEQ ID NO: 49; or (bb) the VH region amino acid sequence comprises SEQ ID NO:50 and the VL region amino acid sequence comprises SEQ ID NO:51; or (cc) the antibody or antigen-binding portion of embodiment 1, wherein the VH region amino acid sequence comprises SEQ ID NO:52 and the VL region amino acid sequence comprises SEQ ID NO:53.
[0173] 3. The antibody or antigen-binding portion of embodiment 1 or 2, which is human or chimeric.
[0174] 4. The antibody or antigen-binding portion of any one of embodiments 1 to 3, which comprises an immunoglobulin constant region.
[0175] 5. The antibody or antigen-binding portion of embodiment 4, wherein the immunoglobulin constant region is IgG, IgE, IgM, IgD, IgA or IgY.
[0176] 6. The antibody or antigen-binding portion of embodiment 5, wherein the immunoglobulin constant region is IgG1, IgG2, IgG3, IgG4, IgA1 or IgA2.
[0177] 7. The antibody or antigen-binding portion of embodiment 4, wherein the immunoglobulin constant region is immunologically inert.
[0178] 8. The antibody or antigen-binding portion of embodiment 4, wherein said immunoglobulin constant region is a wild-type human IgG4 constant region, a human IgG4 constant region comprising the amino acid substitution S228P, a wild-type human IgG1 constant region, a human IgG1 constant region comprising the amino acid substitutions L234A, L235A and G237A, or a wild-type human IgG2 constant region, where numbering is according to EU index as in Kabat.
[0179] 9. The antibody or antigen-binding portion of embodiment 4, wherein the immunoglobulin constant region comprises any one of SEQ ID NOs: 145-149.
[0180] 10. The antibody or antigen-binding portion of any one of embodiments 1 to 9, which is a Fab, Fab', F(ab')2, Fv, scFv, maxibody, minibody, diabody, triabody, tetrabody, or bis-scFv.
[0181] 11. The antibody or antigen-binding portion of any one of embodiments 1 to 10, wherein the antibody is monoclonal.
[0182] 12. The antibody or antigen-binding portion of any one of embodiments 1 to 11, which is tetrameric, tetravalent or multispecific.
[0183] 13. The antibody or antigen-binding portion of any one of embodiments 1 to 12, which is a bispecific antibody or antigen-binding portion that specifically binds to a first antigen and a second antigen, wherein the first antigen is VISTA and the second antigen is not VISTA.
[0184] 14. An immunoconjugate comprising the antibody or antigen-binding portion of any one of embodiments 1 to 13 linked to a therapeutic agent.
[0185] 15. The immunoconjugate of embodiment 14, wherein the therapeutic agent is a cytotoxin, a radioisotope, a chemotherapeutic agent, an immunomodulatory agent, a cytostatic enzyme, a cytolytic enzyme, a therapeutic peptide, a therapeutic nucleic acid, an angiogenesis inhibitor, an antiproliferative agent, or a proapoptotic agent.
[0186] 16. A pharmaceutical composition comprising an antibody or antigen-binding portion according to any one of embodiments 1 to 13 or an immunoconjugate according to embodiment 14 or 15, and a pharma- ceutically acceptable carrier, diluent or excipient.
[0187] 17. An antibody or antigen-binding portion according to any one of embodiments 1 to 13, (a) the VH region amino acid sequence; (b) the VL domain amino acid sequence, or (c) a nucleic acid molecule encoding both the VH region amino acid sequence and the VL region amino acid sequence.
[0188] 18. An expression vector comprising the nucleic acid molecule of embodiment 17.
[0189] 19. A recombinant host cell comprising a nucleic acid molecule according to embodiment 17 or an expression vector according to embodiment 18.
[0190] 20. A method of producing an anti-VISTA antibody or antigen-binding portion thereof, comprising culturing a recombinant host cell comprising the expression vector of embodiment 18 under conditions in which the nucleic acid molecule is expressed, thereby producing the antibody or antigen-binding portion thereof; and and isolating said antibody or antigen-binding portion from said host cell or culture.
[0191] 21. A method for inducing an immune response in a subject, comprising administering to the subject a therapeutically effective amount of an antibody or antigen-binding portion thereof according to any one of embodiments 1 to 13, an immunoconjugate according to embodiment 14 or 15, or a pharmaceutical composition according to embodiment 16.
[0192] 22. The method of embodiment 21, wherein the immune response is an immune response against cancer cells.
[0193] 23. The method of embodiment 21 or 22, wherein the immune response is antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity or antibody-dependent cellular phagocytosis.
[0194] 24. A method for treating or preventing cancer in a subject, comprising administering to the subject a therapeutically effective amount of an antibody or antigen-binding portion thereof according to any one of embodiments 1 to 13, an immunoconjugate according to embodiment 14 or 15, or a pharmaceutical composition according to embodiment 16.
[0195] 25. The method of embodiment 24, wherein the cancer is a hematological malignancy or epithelial cancer.
[0196] 26. The method of embodiment 24, wherein the cancer is squamous cell carcinoma of the head and neck, melanoma, non-small cell lung cancer or colon cancer.
[0197] 27. The method of embodiment 24, wherein the cancer is acute myeloid leukemia (AML).
[0198] 28. The method of any one of embodiments 21-27, wherein VISTA is overexpressed in the subject.
[0199] 29. The method of any one of embodiments 21 to 27, wherein the subject has VISTA overexpressed in immune cells.
[0200] 30. The method of embodiment 29, wherein the immune cells are tumor-infiltrating immune cells.
[0201] 31. The method of embodiment 29 or 30, wherein the immune cells are bone marrow cells or monocytes.
[0202] 32. The method of any one of embodiments 21-31, further comprising administering to the subject an inhibitor of PD-1 or an inhibitor of PD-L1.
[0203] 33. The method of embodiment 32, wherein the inhibitor of PD-1 is an anti-PD-1 antibody or an antigen-binding portion thereof.
[0204] 34. The method of embodiment 32, wherein the inhibitor of PD-L1 is an anti-PD-L1 antibody or an antigen-binding portion thereof.
[0205] 35. An antibody or antigen-binding portion according to any one of embodiments 1 to 13, an immunoconjugate according to embodiment 14 or 15, or a pharmaceutical composition according to embodiment 16, for use as a medicament.
[0206] 36. A method for treating a tumor in a subject, comprising: (a) obtaining a VISTA:PSGL-1 proximity score for a tumor specimen from said subject, (i) obtaining images of tissue excised from said tumor specimen and immunohistochemically stained for VISTA and PSGL-1 expression in such a manner that VISTA stained cells can be distinguished from PSGL-1 stained cells; (ii) defining one or more regions of interest (ROIs) in the image that include tumor cells and tumor stroma, wherein substantially all of the tumor cells and tumor stroma in the image are contained within the defined ROIs; (iii) randomly creating a plurality of sub-regions of substantially the same shape and size across each defined ROI, each of said sub-regions defining an area large enough to include pairs of stained VISTA and PSGL-1 cells that are spatially proximal, and small enough to exclude pairs of stained VISTA and PSGL-1 cells that are not spatially proximal; and (iv) calculating the percentage of all sub-areas that are positive for both VISTA stained cells and PSGL-1 stained cells to generate the VISTA:PSGL-1 proximity score for the tumor specimen; (b) comparing the VISTA:PSGL-1 proximity score of the tumor specimen to a threshold VISTA:PSGL-1 proximity score; (c) classifying the tumor as biomarker positive or biomarker negative, where if the proximity score of the tumor specimen is equal to or greater than the threshold proximity score, the tumor is classified as VISTA:PSGL-1 proximal biomarker positive, and if the obtained score is less than the threshold score, the tumor is classified as VISTA:PSGL-1 proximal biomarker negative; and (d) administering to the subject a therapeutically effective amount of the antibody or antigen-binding portion thereof of any one of embodiments 1 to 13, the immunoconjugate of embodiment 14 or 15, or the pharmaceutical composition of embodiment 16 if the tumor is positive for the VISTA:PSGL-1 proximity biomarker.
Claims
1. 1. A V domain immunoglobulin inhibitor of T cell activation (VISTA) antibody or an antigen-binding portion thereof, comprising a heavy chain variable (VH) region and a light chain variable (VL) region, (a) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO:54, an HCDR2 comprising SEQ ID NO:55, and an HCDR3 comprising SEQ ID NO:56, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO:57, an LCDR2 comprising SEQ ID NO:58, and an LCDR3 comprising SEQ ID NO:59; or (b) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO:60, an HCDR2 comprising SEQ ID NO:61, and an HCDR3 comprising SEQ ID NO:56, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO:57, an LCDR2 comprising SEQ ID NO:58, and an LCDR3 comprising SEQ ID NO:59; or (c) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO:62, an HCDR2 comprising SEQ ID NO:63, and an HCDR3 comprising SEQ ID NO:56, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO:57, an LCDR2 comprising SEQ ID NO:58, and an LCDR3 comprising SEQ ID NO:59; or (d) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO:64, an HCDR2 comprising SEQ ID NO:65, and an HCDR3 comprising SEQ ID NO:66, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO:57, an LCDR2 comprising SEQ ID NO:67, and an LCDR3 comprising SEQ ID NO:68; or (e) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO:69, an HCDR2 comprising SEQ ID NO:70, and an HCDR3 comprising SEQ ID NO:56, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO:57, an LCDR2 comprising SEQ ID NO:67, and an LCDR3 comprising SEQ ID NO:71; or (f) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO:60, an HCDR2 comprising SEQ ID NO:61, and an HCDR3 comprising SEQ ID NO:72, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO:57, an LCDR2 comprising SEQ ID NO:58, and an LCDR3 comprising SEQ ID NO:68; or (g) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO:73, an HCDR2 comprising SEQ ID NO:65, and an HCDR3 comprising SEQ ID NO:74, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO:57, an LCDR2 comprising SEQ ID NO:58, and an LCDR3 comprising SEQ ID NO:71; or (h) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO:64, an HCDR2 comprising SEQ ID NO:75, and an HCDR3 comprising SEQ ID NO:66, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO:57, an LCDR2 comprising SEQ ID NO:76, and an LCDR3 comprising SEQ ID NO:68; or (i) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO:64, an HCDR2 comprising SEQ ID NO:65, and an HCDR3 comprising SEQ ID NO:77, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO:57, an LCDR2 comprising SEQ ID NO:78, and an LCDR3 comprising SEQ ID NO:68; or (j) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO:60, an HCDR2 comprising SEQ ID NO:75, and an HCDR3 comprising SEQ ID NO:56, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO:57, an LCDR2 comprising SEQ ID NO:58, and an LCDR3 comprising SEQ ID NO:68; or (k) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO:54, an HCDR2 comprising SEQ ID NO:65, and an HCDR3 comprising SEQ ID NO:79, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO:80, an LCDR2 comprising SEQ ID NO:58, and an LCDR3 comprising SEQ ID NO:68; or (l) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 81, an HCDR2 comprising SEQ ID NO: 82, and an HCDR3 comprising SEQ ID NO: 83, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 84, an LCDR2 comprising SEQ ID NO: 85, and an LCDR3 comprising SEQ ID NO: 86; or (m) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO:87, an HCDR2 comprising SEQ ID NO:88, and an HCDR3 comprising SEQ ID NO:83, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO:84, an LCDR2 comprising SEQ ID NO:85, and an LCDR3 comprising SEQ ID NO:86; or (n) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 89, an HCDR2 comprising SEQ ID NO: 90, and an HCDR3 comprising SEQ ID NO: 83, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 84, an LCDR2 comprising SEQ ID NO: 85, and an LCDR3 comprising SEQ ID NO: 86; or (o) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO:91, an HCDR2 comprising SEQ ID NO:92, and an HCDR3 comprising SEQ ID NO:83, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO:84, an LCDR2 comprising SEQ ID NO:85, and an LCDR3 comprising SEQ ID NO:86; or (p) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO:93, an HCDR2 comprising SEQ ID NO:94, and an HCDR3 comprising SEQ ID NO:95, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO:96, an LCDR2 comprising SEQ ID NO:85, and an LCDR3 comprising SEQ ID NO:97; or (q) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO:98, an HCDR2 comprising SEQ ID NO:99, and an HCDR3 comprising SEQ ID NO:100, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO:96, an LCDR2 comprising SEQ ID NO:101, and an LCDR3 comprising SEQ ID NO:102; or (r) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 103, an HCDR2 comprising SEQ ID NO: 104, and an HCDR3 comprising SEQ ID NO: 105, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 96, an LCDR2 comprising SEQ ID NO: 106, and an LCDR3 comprising SEQ ID NO: 107; or (s) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 108, an HCDR2 comprising SEQ ID NO: 94, and an HCDR3 comprising SEQ ID NO: 105, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 109, an LCDR2 comprising SEQ ID NO: 85, and an LCDR3 comprising SEQ ID NO: 110; or (t) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO:111, an HCDR2 comprising SEQ ID NO:94, and an HCDR3 comprising SEQ ID NO:112, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO:96, an LCDR2 comprising SEQ ID NO:85, and an LCDR3 comprising SEQ ID NO:113; or (u) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO:87, an HCDR2 comprising SEQ ID NO:94, and an HCDR3 comprising SEQ ID NO:114, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO:115, an LCDR2 comprising SEQ ID NO:85, and an LCDR3 comprising SEQ ID NO:116; or (v) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO:93, an HCDR2 comprising SEQ ID NO:90, and an HCDR3 comprising SEQ ID NO:117, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO:118, an LCDR2 comprising SEQ ID NO:85, and an LCDR3 comprising SEQ ID NO:86; or (w) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 119, an HCDR2 comprising SEQ ID NO: 120, and an HCDR3 comprising SEQ ID NO: 121, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 57, an LCDR2 comprising SEQ ID NO: 58, and an LCDR3 comprising SEQ ID NO: 122; or (x) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 123, an HCDR2 comprising SEQ ID NO: 124, and an HCDR3 comprising SEQ ID NO: 125, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 126, an LCDR2 comprising SEQ ID NO: 127, and an LCDR3 comprising SEQ ID NO: 128; or (y) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 123, an HCDR2 comprising SEQ ID NO: 124, and an HCDR3 comprising SEQ ID NO: 129, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 57, an LCDR2 comprising SEQ ID NO: 58, and an LCDR3 comprising SEQ ID NO: 130; or (z) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 131, an HCDR2 comprising SEQ ID NO: 132, and an HCDR3 comprising SEQ ID NO: 133, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 126, an LCDR2 comprising SEQ ID NO: 134, and an LCDR3 comprising SEQ ID NO: 135; or (aa) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO: 131, an HCDR2 comprising SEQ ID NO: 132, and an HCDR3 comprising SEQ ID NO: 136, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO: 57, an LCDR2 comprising SEQ ID NO: 58, and an LCDR3 comprising SEQ ID NO: 137; or (bb) the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO:54, an HCDR2 comprising SEQ ID NO:138, and an HCDR3 comprising SEQ ID NO:139, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO:57, an LCDR2 comprising SEQ ID NO:58, and an LCDR3 comprising SEQ ID NO:140; or (cc) the antibody or antigen-binding portion thereof, wherein the VH region amino acid sequence comprises an HCDR1 comprising SEQ ID NO:81, an HCDR2 comprising SEQ ID NO:82, and an HCDR3 comprising SEQ ID NO:141, and the VL region amino acid sequence comprises an LCDR1 comprising SEQ ID NO:142, an LCDR2 comprising SEQ ID NO:143, and an LCDR3 comprising SEQ ID NO:
144.
2. (a) the VH region amino acid sequence comprises SEQ ID NO:1 and the VL region amino acid sequence comprises SEQ ID NO:2; or (b) the VH region amino acid sequence comprises SEQ ID NO:3 and the VL region amino acid sequence comprises SEQ ID NO:2; or (c) the VH region amino acid sequence comprises SEQ ID NO:4 and the VL region amino acid sequence comprises SEQ ID NO:2; or (d) the VH region amino acid sequence comprises SEQ ID NO:5 and the VL region amino acid sequence comprises SEQ ID NO:6; or (e) the VH region amino acid sequence comprises SEQ ID NO:7 and the VL region amino acid sequence comprises SEQ ID NO:8; or (f) the VH region amino acid sequence comprises SEQ ID NO:9 and the VL region amino acid sequence comprises SEQ ID NO:10; or (g) the VH region amino acid sequence comprises SEQ ID NO:11 and the VL region amino acid sequence comprises SEQ ID NO:12; or (h) the VH region amino acid sequence comprises SEQ ID NO:13 and the VL region amino acid sequence comprises SEQ ID NO:14; or (i) the VH region amino acid sequence comprises SEQ ID NO: 15 and the VL region amino acid sequence comprises SEQ ID NO: 16; or (j) the VH region amino acid sequence comprises SEQ ID NO: 17 and the VL region amino acid sequence comprises SEQ ID NO: 18; or (k) the VH region amino acid sequence comprises SEQ ID NO: 19 and the VL region amino acid sequence comprises SEQ ID NO: 20; or (l) the VH region amino acid sequence comprises SEQ ID NO:21 and the VL region amino acid sequence comprises SEQ ID NO:22; or (m) the VH region amino acid sequence comprises SEQ ID NO:23 and the VL region amino acid sequence comprises SEQ ID NO:22; or (n) the VH region amino acid sequence comprises SEQ ID NO:24 and the VL region amino acid sequence comprises SEQ ID NO:22; or (o) the VH region amino acid sequence comprises SEQ ID NO:25 and the VL region amino acid sequence comprises SEQ ID NO:22; or (p) the VH region amino acid sequence comprises SEQ ID NO:26 and the VL region amino acid sequence comprises SEQ ID NO:27; or (q) the VH region amino acid sequence comprises SEQ ID NO:28 and the VL region amino acid sequence comprises SEQ ID NO:29; or (r) the VH region amino acid sequence comprises SEQ ID NO:30 and the VL region amino acid sequence comprises SEQ ID NO:31; or (s) the VH region amino acid sequence comprises SEQ ID NO:32 and the VL region amino acid sequence comprises SEQ ID NO:33; or (t) the VH region amino acid sequence comprises SEQ ID NO:34 and the VL region amino acid sequence comprises SEQ ID NO:35; or (u) the VH region amino acid sequence comprises SEQ ID NO: 36 and the VL region amino acid sequence comprises SEQ ID NO: 37; or (v) the VH region amino acid sequence comprises SEQ ID NO:38 and the VL region amino acid sequence comprises SEQ ID NO:39; or (w) the VH region amino acid sequence comprises SEQ ID NO:40 and the VL region amino acid sequence comprises SEQ ID NO:41; or (x) the VH region amino acid sequence comprises SEQ ID NO: 42 and the VL region amino acid sequence comprises SEQ ID NO: 43; or (y) the VH region amino acid sequence comprises SEQ ID NO:44 and the VL region amino acid sequence comprises SEQ ID NO:45; or (z) the VH region amino acid sequence comprises SEQ ID NO:46 and the VL region amino acid sequence comprises SEQ ID NO:47; or (aa) the VH region amino acid sequence comprises SEQ ID NO:48 and the VL region amino acid sequence comprises SEQ ID NO:49; or (bb) the VH region amino acid sequence comprises SEQ ID NO:50 and the VL region amino acid sequence comprises SEQ ID NO:51; or (cc) The antibody or antigen-binding portion of claim 1, wherein the VH region amino acid sequence comprises SEQ ID NO:52 and the VL region amino acid sequence comprises SEQ ID NO:
53.
3. 3. The antibody or antigen-binding portion of claim 1 or 2, which is human or chimeric.
4. The antibody or antigen-binding portion of any one of claims 1 to 3, which comprises an immunoglobulin constant region.
5. 5. The antibody or antigen-binding portion of claim 4, wherein the immunoglobulin constant region is IgG, IgE, IgM, IgD, IgA or IgY.
6. 6. The antibody or antigen-binding portion of claim 5, wherein the immunoglobulin constant region is IgG1, IgG2, IgG3, IgG4, IgA1 or IgA2.
7. The antibody or antigen-binding portion of claim 4, wherein the immunoglobulin constant region is immunologically inert.
8. 5. The antibody or antigen-binding portion of claim 4, wherein the immunoglobulin constant region is a wild-type human IgG4 constant region, a human IgG4 constant region comprising the amino acid substitution S228P, a wild-type human IgG1 constant region, a human IgG1 constant region comprising the amino acid substitutions L234A, L235A and G237A, or a wild-type human IgG2 constant region, wherein the numbering is according to the EU index as in Kabat.
9. The antibody or antigen-binding portion of claim 4, wherein the immunoglobulin constant region comprises any one of SEQ ID NOs: 145-149.
10. Fab, Fab', F(ab') 2 10. The antibody or antigen-binding portion of any one of claims 1 to 9, which is an Fv, scFv, maxibody, minibody, diabody, triabody, tetrabody, or bis-scFv.
11. The antibody or antigen-binding portion of any one of claims 1 to 10, wherein the antibody is monoclonal.
12. The antibody or antigen-binding portion of any one of claims 1 to 11, which is tetrameric, tetravalent or multispecific.
13. 13. The antibody or antigen-binding portion of any one of claims 1 to 12, which is a bispecific antibody or antigen-binding portion that specifically binds to a first antigen and a second antigen, wherein the first antigen is VISTA and the second antigen is not VISTA.
14. An immunoconjugate comprising the antibody or antigen-binding portion of any one of claims 1 to 13 linked to a therapeutic agent.
15. 15. The immunoconjugate of claim 14, wherein the therapeutic agent is a cytotoxin, a radioisotope, a chemotherapeutic agent, an immunomodulatory agent, a cytostatic enzyme, a cytolytic enzyme, a therapeutic peptide, a therapeutic nucleic acid, an angiogenesis inhibitor, an anti-proliferative agent, or a pro-apoptotic agent.
16. A pharmaceutical composition comprising an antibody or antigen-binding portion thereof according to any one of claims 1 to 13 or an immunoconjugate according to claim 14 or 15, and a pharma- ceutically acceptable carrier, diluent or excipient.
17. An antibody or antigen-binding portion of any one of claims 1 to 13, (a) the VH region amino acid sequence; (b) the VL domain amino acid sequence; or (c) both the VH domain amino acid sequence and the VL domain amino acid sequence A nucleic acid molecule encoding the
18. An expression vector comprising the nucleic acid molecule of claim 17.
19. 19. A recombinant host cell comprising the nucleic acid molecule of claim 17 or the expression vector of claim 18.
20. 1. A method of producing an anti-VISTA antibody or antigen-binding portion thereof, comprising: Culturing a recombinant host cell comprising the expression vector of claim 18 under conditions in which the nucleic acid molecule is expressed, thereby producing the antibody or antigen-binding portion; and and isolating said antibody or antigen-binding portion from said host cell or culture.
21. 19. A method for inducing an immune response in a subject, comprising administering to the subject a therapeutically effective amount of the antibody or antigen-binding portion of any one of claims 1 to 13, the immunoconjugate of claim 14 or 15, or the pharmaceutical composition of claim 16.
22. 22. The method of claim 21, wherein the immune response is an immune response against cancer cells.
23. 23. The method of claim 21 or 22, wherein the immune response is antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity or antibody-dependent cellular phagocytosis.
24. 19. A method for treating or preventing cancer in a subject, comprising administering to the subject a therapeutically effective amount of the antibody or antigen-binding portion of any one of claims 1 to 13, the immunoconjugate of claim 14 or 15, or the pharmaceutical composition of claim 16.
25. 25. The method of claim 24, wherein the cancer is a hematological malignancy or an epithelial cancer.
26. 25. The method of claim 24, wherein the cancer is squamous cell carcinoma of the head and neck, melanoma, non-small cell lung cancer, or colon cancer.
27. 25. The method of claim 24, wherein the cancer is acute myeloid leukemia (AML).
28. The method of any one of claims 21 to 27, wherein VISTA is overexpressed in the subject.
29. The method of any one of claims 21 to 27, wherein VISTA is overexpressed in immune cells in the subject.
30. 30. The method of claim 29, wherein the immune cells are tumor-infiltrating immune cells.
31. 31. The method of claim 29 or 30, wherein the immune cell is a bone marrow cell or a monocyte.
32. The method of any one of claims 21 to 31, further comprising administering to the subject an inhibitor of PD-1 or an inhibitor of PD-L1.
33. 33. The method of claim 32, wherein the inhibitor of PD-1 is an anti-PD-1 antibody or an antigen-binding portion thereof.
34. The method of claim 32, wherein the inhibitor of PD-L1 is an anti-PD-L1 antibody or an antigen-binding portion thereof.
35. An antibody or antigen-binding portion according to any one of claims 1 to 13, an immunoconjugate according to claim 14 or 15, or a pharmaceutical composition according to claim 16, for use as a medicament.
36. 1. A method for treating a tumor in a subject, comprising: (a) obtaining a VISTA:PSGL-1 proximity score for a tumor specimen from said subject, (i) obtaining images of tissue excised from said tumor specimen and immunohistochemically stained for VISTA and PSGL-1 expression such that stained VISTA cells can be distinguished from stained PSGL-1 cells; (ii) defining one or more regions of interest (ROIs) in the image that include tumor cells and tumor stroma, wherein substantially all of the tumor cells and tumor stroma in the image are contained within the defined ROIs; (iii) randomly creating a plurality of sub-regions of substantially the same shape and size across each defined ROI, each of said sub-regions defining an area large enough to include pairs of stained VISTA and PSGL-1 cells that are spatially proximal, and small enough to exclude pairs of stained VISTA and PSGL-1 cells that are not spatially proximal; and (iv) assigning said VISTA:PSGL-1 proximity score to said tumor specimen by a step comprising: calculating the percent of all said subregions that are positive for both VISTA staining cells and PSGL-1 staining cells to generate said VISTA:PSGL-1 proximity score for said tumor specimen; (b) comparing the VISTA:PSGL-1 proximity score of the tumor specimen to a threshold VISTA:PSGL-1 proximity score; (c) classifying the tumor as biomarker positive or biomarker negative, where if the proximity score of the tumor specimen is equal to or greater than the threshold proximity score, the tumor is classified as VISTA:PSGL-1 proximity biomarker positive, and if the obtained score is less than the threshold score, the tumor is classified as VISTA:PSGL-1 proximity biomarker negative; and (d) administering to the subject a therapeutically effective amount of the antibody or antigen-binding portion of any one of claims 1 to 13, the immunoconjugate of claim 14 or 15, or the pharmaceutical composition of claim 16 if the tumor is positive for the VISTA:PSGL-1 proximity biomarker.
Citation Information
Patent Citations
Vista antigen-binding molecules
US10633456B1
Anti-Vista Antibodies And Fragments, Uses Thereof, And Methods Of Identifying Same
US20170320950A1
Antibodies binding to vista at acidic ph
WO2020014327A2
